DE3413608A1
(en)
*
|
1984-04-11 |
1985-10-24 |
Hoechst Ag, 6230 Frankfurt |
IMPLANTABLE PREPARATIONS OF REGULATORY PEPTIDES WITH CONTROLLED RELEASE AND METHOD FOR THE PRODUCTION THEREOF
|
IL79134A
(en)
*
|
1985-07-29 |
1991-06-10 |
American Cyanamid Co |
Continuous release peptide implants for parenteral administration
|
US5137874A
(en)
*
|
1985-07-29 |
1992-08-11 |
American Cyanamid Co. |
Partially coated C10 -C20 fatty acid salts of peptides having molecular weights up to about 5,000
|
US4761289A
(en)
*
|
1986-10-10 |
1988-08-02 |
International Minerals & Chemical Corp. |
Sustained release implant and method for preparing same
|
DE3855869T2
(en)
|
1987-02-20 |
1997-10-02 |
Genentech Inc |
Methods and preparations for the use of HIV env polypeptides and antibodies
|
DE3712095A1
(en)
*
|
1987-04-10 |
1988-10-20 |
Lentia Gmbh |
BINDER-FREE GRANULES WITH DELAYED DELIVERY OF ACTIVE SUBSTANCES
|
DE3811231A1
(en)
*
|
1988-04-02 |
1989-10-12 |
Beiersdorf Ag |
Surgical implants
|
EP0423484B1
(en)
*
|
1989-10-16 |
1993-11-03 |
PCD-Polymere Gesellschaft m.b.H. |
Tablet with sustained release
|
US5470582A
(en)
*
|
1992-02-07 |
1995-11-28 |
Syntex (U.S.A.) Inc. |
Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
|
JP2651320B2
(en)
*
|
1992-07-16 |
1997-09-10 |
田辺製薬株式会社 |
Method for producing sustained-release microsphere preparation
|
US5877016A
(en)
|
1994-03-18 |
1999-03-02 |
Genentech, Inc. |
Human trk receptors and neurotrophic factor inhibitors
|
US5708142A
(en)
|
1994-05-27 |
1998-01-13 |
Genentech, Inc. |
Tumor necrosis factor receptor-associated factors
|
DE4423131A1
(en)
*
|
1994-07-01 |
1996-01-04 |
Bayer Ag |
New hIL-4 mutant proteins as antagonists or partial agonists of human interleukin 4
|
US6093697A
(en)
*
|
1994-11-07 |
2000-07-25 |
The University Of Virginia Patent Foundation |
Synthetic insulin mimetic substances
|
US5674888A
(en)
*
|
1995-06-07 |
1997-10-07 |
University Of California |
Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division
|
US5599535A
(en)
*
|
1995-06-07 |
1997-02-04 |
Regents Of The University Of California |
Methods for the cyto-protection of the trabecular meshwork
|
US6020473A
(en)
*
|
1995-08-25 |
2000-02-01 |
Genentech, Inc. |
Nucleic acids encoding variants of vascular endothelial cell growth factor
|
US7005505B1
(en)
|
1995-08-25 |
2006-02-28 |
Genentech, Inc. |
Variants of vascular endothelial cell growth factor
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
WO1998011913A1
(en)
*
|
1996-09-16 |
1998-03-26 |
Dalhousie University |
Use of igf-i for the treatment of polycystic kidney disease and related indications
|
EP2230307A1
(en)
|
1996-10-25 |
2010-09-22 |
Human Genome Sciences, Inc. |
Neutrokine alpha
|
US7390891B1
(en)
|
1996-11-15 |
2008-06-24 |
Amgen Inc. |
Polynucleotides encoding a telomerase component TP2
|
EP2332975A1
(en)
|
1997-05-30 |
2011-06-15 |
Human Genome Sciences, Inc. |
Human proteins
|
US6342220B1
(en)
|
1997-08-25 |
2002-01-29 |
Genentech, Inc. |
Agonist antibodies
|
ATE442385T1
(en)
|
1997-09-17 |
2009-09-15 |
Human Genome Sciences Inc |
INTERLEUKIN-17 RECEPTOR-LIKE PROTEIN
|
US5906979A
(en)
*
|
1998-01-27 |
1999-05-25 |
Insmed Pharmaceuticals, Inc. |
Compositions and methods for treating metabolic diseases characterized by hyperandrogenism and/or anovulation and/or infertility
|
EP2050762A3
(en)
|
1998-03-10 |
2009-07-08 |
Genentech, Inc. |
Human cornichon-like protein and nucleic acids encoding it
|
EP1064382B1
(en)
|
1998-03-17 |
2008-08-20 |
Genentech, Inc. |
Polypeptides homologous to vegf and bmp1
|
EP1982990A1
(en)
|
1998-03-19 |
2008-10-22 |
Human Genome Sciences, Inc. |
Cytokine receptor common gamma chain like
|
US5973119A
(en)
*
|
1998-06-05 |
1999-10-26 |
Amgen Inc. |
Cyclin E genes and proteins
|
US6344541B1
(en)
|
1998-09-25 |
2002-02-05 |
Amgen Inc. |
DKR polypeptides
|
AUPP785098A0
(en)
|
1998-12-21 |
1999-01-21 |
Victor Chang Cardiac Research Institute, The |
Treatment of heart disease
|
US6303749B1
(en)
|
1999-01-29 |
2001-10-16 |
Amgen Inc. |
Agouti and agouti-related peptide analogs
|
US8624010B1
(en)
|
1999-02-03 |
2014-01-07 |
Steven K. Yoshinaga |
Nucleic acids encoding B7RP1
|
US7435796B1
(en)
|
1999-02-03 |
2008-10-14 |
Amgen Inc. |
Antibodies which bind B7RP1
|
SI2332976T1
(en)
|
1999-02-03 |
2014-08-29 |
Amgen Inc. |
Novel polypeptides involved in immune response
|
US7708993B2
(en)
|
1999-02-03 |
2010-05-04 |
Amgen Inc. |
Polypeptides involved in immune response
|
CA2363779A1
(en)
|
1999-02-26 |
2000-08-31 |
Human Genome Sciences, Inc. |
Human endokine alpha and methods of use
|
AU3770800A
(en)
|
1999-03-26 |
2000-10-16 |
Amgen, Inc. |
Beta secretase genes and polypeptides
|
US6635249B1
(en)
|
1999-04-23 |
2003-10-21 |
Cenes Pharmaceuticals, Inc. |
Methods for treating congestive heart failure
|
KR100674528B1
(en)
|
1999-06-28 |
2007-01-29 |
제넨테크, 인크. |
Methods for Making Apo-2 Ligand Using Divalent Metal Ions
|
US7459540B1
(en)
|
1999-09-07 |
2008-12-02 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
US7408047B1
(en)
|
1999-09-07 |
2008-08-05 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
US7514239B2
(en)
|
2000-03-28 |
2009-04-07 |
Amgen Inc. |
Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
|
EP1276849A4
(en)
|
2000-04-12 |
2004-06-09 |
Human Genome Sciences Inc |
Albumin fusion proteins
|
WO2001096528A2
(en)
|
2000-06-15 |
2001-12-20 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor delta and epsilon
|
EP2077276A1
(en)
|
2000-06-23 |
2009-07-08 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogensis
|
EP2042597B1
(en)
|
2000-06-23 |
2014-05-07 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
WO2002000724A2
(en)
|
2000-06-28 |
2002-01-03 |
Amgen, Inc. |
Thymic stromal lymphopoietin receptor molecules and uses thereof
|
JP4236925B2
(en)
|
2000-11-28 |
2009-03-11 |
アムジエン・インコーポレーテツド |
Novel polypeptides involved in immune responses
|
US6989247B2
(en)
|
2000-11-28 |
2006-01-24 |
Celltech R & D, Inc. |
Compositions and methods for diagnosing or treating psoriasis
|
US7087726B2
(en)
|
2001-02-22 |
2006-08-08 |
Genentech, Inc. |
Anti-interferon-α antibodies
|
AUPR546801A0
(en)
|
2001-06-05 |
2001-06-28 |
Commonwealth Scientific And Industrial Research Organisation |
Recombinant antibodies
|
PL222211B1
(en)
|
2001-06-26 |
2016-07-29 |
Amgen Fremont Inc |
Antibodies to opgl
|
US7767786B2
(en)
|
2001-08-24 |
2010-08-03 |
Neuren Pharmaceuticals Ltd. |
Neural regeneration peptides and methods for their use in treatment of neural injury or degeneration
|
CN1575338B
(en)
|
2001-08-29 |
2012-05-16 |
杰南技术公司 |
Bv8 nucleic acids and polypeptides with mitogenic activity
|
EP2050460A1
(en)
|
2001-09-24 |
2009-04-22 |
Imperial Innovations Limited |
PYY and agonists thereof for modification of feeding behaviour
|
EP2348043A1
(en)
|
2001-10-02 |
2011-07-27 |
Genentech, Inc. |
APO-2 ligand variants and uses thereof
|
US7138370B2
(en)
|
2001-10-11 |
2006-11-21 |
Amgen Inc. |
Specific binding agents of human angiopoietin-2
|
US7521053B2
(en)
|
2001-10-11 |
2009-04-21 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
EP2316485A1
(en)
|
2001-10-12 |
2011-05-04 |
Schering Corporation |
Use of bispecific antibodies to regulate immune responses
|
EP1450847B1
(en)
|
2001-11-13 |
2010-09-29 |
Genentech, Inc. |
APO2 ligand/ TRAIL formulations and uses thereof
|
EP2277889B1
(en)
|
2001-12-21 |
2014-07-09 |
Human Genome Sciences, Inc. |
Fusion proteins of albumin and interferon beta
|
JP4733922B2
(en)
|
2002-01-10 |
2011-07-27 |
インペリアル・イノベ−ションズ・リミテッド |
Correction of eating behavior
|
US8058233B2
(en)
|
2002-01-10 |
2011-11-15 |
Oregon Health And Science University |
Modification of feeding behavior using PYY and GLP-1
|
US7662924B2
(en)
|
2002-02-22 |
2010-02-16 |
The Board Of Trustees Of The University Of Illinois |
Beta chain-associated regulator of apoptosis
|
PL375041A1
(en)
|
2002-04-05 |
2005-11-14 |
Amgen Inc. |
Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
|
ATE512989T1
(en)
|
2002-04-15 |
2011-07-15 |
Chugai Pharmaceutical Co Ltd |
METHOD FOR PRODUCING SCDB LIBRARIES
|
AU2003235833A1
(en)
|
2002-04-26 |
2003-11-10 |
Chugai Seiyaku Kabushiki Kaisha |
Method of screening agonistic antibody
|
AU2002304965A1
(en)
|
2002-05-24 |
2003-12-12 |
Zensun (Shanghai) Sci-Tech.Ltd |
Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
|
EP2305710A3
(en)
|
2002-06-03 |
2013-05-29 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
CA2489348A1
(en)
|
2002-06-24 |
2003-12-31 |
Genentech, Inc. |
Apo-2 ligand/trail variants and uses thereof
|
NZ593428A
(en)
|
2002-09-06 |
2013-01-25 |
Amgen Inc |
Therapeutic human anti-il-1r1 monoclonal antibody
|
US9809654B2
(en)
|
2002-09-27 |
2017-11-07 |
Vaccinex, Inc. |
Targeted CD1d molecules
|
WO2004034988A2
(en)
|
2002-10-16 |
2004-04-29 |
Amgen Inc. |
Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors
|
AU2003298816C1
(en)
|
2002-12-02 |
2010-12-16 |
Amgen Fremont, Inc. |
Antibodies directed to Tumor Necrosis Factor and uses thereof
|
WO2004060911A2
(en)
|
2002-12-30 |
2004-07-22 |
Amgen Inc. |
Combination therapy with co-stimulatory factors
|
GB0300571D0
(en)
|
2003-01-10 |
2003-02-12 |
Imp College Innovations Ltd |
Modification of feeding behaviour
|
EP1592387A4
(en)
|
2003-01-24 |
2009-05-06 |
Elan Pharm Inc |
Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
|
JP4912144B2
(en)
|
2003-03-12 |
2012-04-11 |
ジェネンテック, インコーポレイテッド |
Use of BV8 and / or EG-VEGF to promote hematopoiesis
|
AU2004224390A1
(en)
|
2003-03-19 |
2004-10-07 |
Abgenix, Inc. |
Antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen and uses thereof
|
US7375076B2
(en)
|
2003-05-20 |
2008-05-20 |
The Regents Of The University Of Michigan |
Methods of reducing vascular permeability in tissue by inhibition of tissue plasminogen activator (tPA) and tPA inhibitors useful therein
|
BRPI0411852A
(en)
|
2003-06-27 |
2006-05-23 |
Abgenix Inc |
antibodies directed to epidermal growth factor receptor deletion mutants and their uses
|
JP5105874B2
(en)
|
2003-07-18 |
2012-12-26 |
アムジエン・インコーポレーテツド |
Specific binding factor for hepatocyte growth factor
|
NZ545940A
(en)
|
2003-09-12 |
2009-12-24 |
Tercica Inc |
Methods for treatment of insulin-like growth factor-1 (IGF-1) deficiency
|
WO2005035753A1
(en)
|
2003-10-10 |
2005-04-21 |
Chugai Seiyaku Kabushiki Kaisha |
Double specific antibodies substituting for functional protein
|
AU2003271186A1
(en)
|
2003-10-14 |
2005-04-27 |
Chugai Seiyaku Kabushiki Kaisha |
Double specific antibodies substituting for functional protein
|
EP1684791A4
(en)
|
2003-10-27 |
2009-07-01 |
Amgen Inc |
Compositions and methods to modulate an immune response to an immunogenic therapeutic agent
|
AU2005211362B2
(en)
|
2004-02-02 |
2008-03-13 |
Ambrx, Inc. |
Modified human interferon polypeptides and their uses
|
AU2005319099B2
(en)
|
2004-02-02 |
2010-09-16 |
Ambrx, Inc. |
Modified human growth hormone
|
WO2005076843A2
(en)
|
2004-02-06 |
2005-08-25 |
Elan Pharmaceuticals, Inc. |
Methods and compositions for treating tumors and metastatic disease
|
US7807176B2
(en)
|
2004-03-19 |
2010-10-05 |
Genomidea, Inc. |
Polypeptide promoting vascular endothelial cell growth
|
CA2564989C
(en)
|
2004-03-19 |
2014-05-27 |
Amgen, Inc. |
Reducing the risk of human and anti-human antibodies through v gene manipulation
|
MY162179A
(en)
|
2004-04-01 |
2017-05-31 |
Elan Pharm Inc |
Steroid sparing agents and methods of using same
|
EP1598428A1
(en)
|
2004-05-18 |
2005-11-23 |
Georg Dewald |
Methods and kits to detect Hereditary angioedema type III
|
AU2005247943A1
(en)
|
2004-05-23 |
2005-12-08 |
Gerard M. Housey |
Theramutein modulators
|
CA2567405A1
(en)
|
2004-05-25 |
2005-12-08 |
Stryker Corporation |
Use of morphogenic proteins for treating cartilage defects
|
CA2568952C
(en)
|
2004-06-18 |
2019-05-21 |
Ambrx, Inc. |
Novel antigen-binding polypeptides and their uses
|
ATE501252T1
(en)
|
2004-06-22 |
2011-03-15 |
Univ Illinois |
METHOD FOR INHIBITING TUMOR CELL GROWTH USING FOXM1 SIRNS
|
ES2395094T3
(en)
|
2004-06-24 |
2013-02-08 |
Biogen Idec Ma Inc. |
Treatment of conditions that involve demyelination
|
ME00226B
(en)
|
2004-07-15 |
2011-02-10 |
Medarex Llc |
Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
|
US7846438B2
(en)
|
2004-08-03 |
2010-12-07 |
Biogen Idec Ma Inc. |
Methods of promoting neurite outgrowth with soluble TAJ polypeptides
|
WO2006015373A2
(en)
|
2004-08-04 |
2006-02-09 |
Amgen Inc |
Antibodies to dkk-1
|
CA2577442A1
(en)
|
2004-08-17 |
2006-03-02 |
The Johns Hopkins University |
Pde5 inhibitor compositions and methods for treating cardiac indications
|
CN101072580B
(en)
|
2004-10-06 |
2012-08-22 |
农业生物技术有限公司 |
Antibody production method
|
EP1810687A4
(en)
|
2004-10-15 |
2009-04-01 |
Univ Mie |
Liver regeneration/repair controlling agent
|
WO2006055638A2
(en)
|
2004-11-17 |
2006-05-26 |
Abgenix, Inc. |
Fully human monoclonal antibodies to il-13
|
US8642596B2
(en)
|
2004-12-06 |
2014-02-04 |
Siga Technologies, Inc. |
Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arena viruses
|
ATE504602T1
(en)
|
2004-12-20 |
2011-04-15 |
Amgen Fremont Inc |
BINDING PROTEINS SPECIFIC TO HUMAN MATRIPTASE
|
AU2005319382B2
(en)
|
2004-12-21 |
2011-04-07 |
Astrazeneca Ab |
Antibodies directed to angiopoietin-2 and uses thereof
|
JP5425398B2
(en)
|
2004-12-22 |
2014-02-26 |
アンブレツクス・インコーポレイテツド |
Compositions comprising unnatural amino acids and polypeptides, methods relating to unnatural amino acids and polypeptides, and uses of unnatural amino acids and polypeptides
|
EP1851245B1
(en)
|
2005-01-26 |
2012-10-10 |
Amgen Fremont Inc. |
Antibodies against interleukin-1 beta
|
DK2824183T3
(en)
|
2005-04-08 |
2020-09-28 |
Chugai Pharmaceutical Co Ltd |
Process for the production of bispecific antibodies
|
US20080009546A1
(en)
|
2005-05-06 |
2008-01-10 |
Chevron U.S.A. Inc. |
Diamondoid derivatives possessing therapeutic activity in the treatment of neurologic disorders
|
CA2605508A1
(en)
|
2005-05-12 |
2006-11-23 |
Wisconsin Alumni Research Foundation |
Blockade of pin1 prevents cytokine production by activated immune cells
|
US8431110B2
(en)
|
2005-05-23 |
2013-04-30 |
Hmi Medical Innovations, Llc. |
Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
|
US20090028854A1
(en)
|
2005-06-10 |
2009-01-29 |
Chugai Seiyaku Kabushiki Kaisha |
sc(Fv)2 SITE-DIRECTED MUTANT
|
JP5068167B2
(en)
|
2005-06-10 |
2012-11-07 |
中外製薬株式会社 |
Stabilizer for protein preparation containing meglumine and use thereof
|
ES2776657T3
(en)
|
2005-06-14 |
2020-07-31 |
Amgen Inc |
Self-buffering protein formulations
|
PT2314623E
(en)
|
2005-06-21 |
2012-10-02 |
Xoma Technology Ltd |
Il-1beta binding antibodies and fragments thereof
|
MX2008000253A
(en)
|
2005-07-08 |
2008-04-02 |
Biogen Idec Inc |
Sp35 antibodies and uses thereof.
|
EP2388277A3
(en)
|
2005-07-18 |
2013-03-20 |
Amgen, Inc |
Human anti-B7RP1 neutralizing antibodies
|
CN101600475A
(en)
|
2005-07-27 |
2009-12-09 |
佛罗里达大学研究基金会有限公司 |
Revise the miniaturization compound and the use thereof of protein false folding
|
KR20140077946A
(en)
|
2005-10-13 |
2014-06-24 |
휴먼 게놈 사이언시즈, 인코포레이티드 |
Methods and compositions for use in treatment of patients with autoantibody positive diseases
|
CA2625773C
(en)
|
2005-10-14 |
2015-05-12 |
Fukuoka University |
Inhibition of interleukin-6 (il-6) receptor promotes pancreatic islet transplantation
|
BRPI0617664B8
(en)
|
2005-10-21 |
2021-05-25 |
Chugai Pharmaceutical Co Ltd |
use of an antibody recognizing IL-6 for the production of a pharmaceutical composition to treat myocardial infarction or suppress left ventricular remodeling after myocardial infarction
|
MX2008005764A
(en)
|
2005-11-04 |
2008-11-18 |
Biogen Idec Inc |
Methods for promoting neurite outgrowth and survival of dopaminergic neurons.
|
JP2009515897A
(en)
|
2005-11-10 |
2009-04-16 |
キュラジェン コーポレイション |
Methods of treating ovarian and renal cancer using antibodies to immunoglobulin domains of murine domain and mucin domain 1 (TIM-1) antigen
|
EP1964574B1
(en)
|
2005-11-14 |
2016-09-07 |
Cellmid Limited |
Method for treatment or prevention of disease associated with functional disorder of regulatory t cell
|
AR056806A1
(en)
|
2005-11-14 |
2007-10-24 |
Amgen Inc |
RANKL- PTH / PTHRP ANTIBODY CHEMICAL MOLECULES
|
AR057582A1
(en)
|
2005-11-15 |
2007-12-05 |
Nat Hospital Organization |
AGENTS TO DELETE INDUCTION OF CYTOTOXIC T LYMPHOCYTES
|
EP1951890A4
(en)
|
2005-11-16 |
2009-06-24 |
Ambrx Inc |
Methods and compositions comprising non-natural amino acids
|
WO2007061029A1
(en)
|
2005-11-25 |
2007-05-31 |
Keio University |
Therapeutic agent for prostate cancer
|
US20070213264A1
(en)
|
2005-12-02 |
2007-09-13 |
Mingdong Zhou |
Neuregulin variants and methods of screening and using thereof
|
JP5312039B2
(en)
|
2005-12-02 |
2013-10-09 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
Treatment of conditions involving demyelination
|
US8158588B2
(en)
|
2005-12-05 |
2012-04-17 |
Simon Delagrave |
Loop-variant PDZ domains as biotherapeutics, diagnostics and research reagents
|
RS52357B
(en)
|
2005-12-13 |
2012-12-31 |
Medimmune Limited |
Binding proteins specific for insulin-like growth factors and uses thereof
|
WO2007068895A1
(en)
|
2005-12-15 |
2007-06-21 |
Astrazeneca Ab |
Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer
|
EP1981525B1
(en)
|
2005-12-30 |
2015-01-21 |
Zensun (Shanghai) Science and Technology Limited |
Extended release of neuregulin for improved cardiac function
|
CN101405389A
(en)
|
2006-01-17 |
2009-04-08 |
生物载体株式会社 |
Novel protein expression system
|
CN103215293B
(en)
|
2006-01-27 |
2015-10-28 |
比奥根Ma公司 |
NOGO receptor antagonist
|
EP1990060B1
(en)
|
2006-01-27 |
2016-09-28 |
Keio University |
Therapeutic agents for diseases associated involving choroidal neovascularization
|
WO2007116962A1
(en)
|
2006-04-07 |
2007-10-18 |
Osaka University |
Muscle regeneration promoter
|
TW200813091A
(en)
|
2006-04-10 |
2008-03-16 |
Amgen Fremont Inc |
Targeted binding agents directed to uPAR and uses thereof
|
EP2035030A2
(en)
|
2006-05-17 |
2009-03-18 |
Stryker Corporation |
Use of a soluble morphogenic protein complex for treating cartilage defects
|
ES2429225T3
(en)
|
2006-05-17 |
2013-11-13 |
The Ludwig Institute For Cancer Research |
Anti-VEGF-B antibodies for the treatment or prophylaxis of type II diabetes or metabolic syndrome
|
EP2049570B1
(en)
|
2006-06-01 |
2016-08-10 |
President and Fellows of Harvard College |
Purification of a bivalently active antibody using a non-chromatographic method
|
CN101500608A
(en)
|
2006-06-08 |
2009-08-05 |
中外制药株式会社 |
Preventive or remedy for inflammatory disease
|
TW200808351A
(en)
|
2006-07-13 |
2008-02-16 |
Chugai Pharmaceutical Co Ltd |
Cell death-inducing agents
|
JP5175729B2
(en)
|
2006-07-21 |
2013-04-03 |
中外製薬株式会社 |
Kidney disease treatment
|
US20100105610A1
(en)
|
2006-07-28 |
2010-04-29 |
Children's Memorial Hospital |
Methods of Inhibiting Tumor Cell Aggressiveness Using the Microenvironment of Human Embryonic Stem Cells
|
CL2007002225A1
(en)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
SPECIFIC UNION AGENT FOR A RECEIVER OF THE GROWTH FACTOR DERIVED FROM PLATES (PDGFR-ALFA); NUCLEIC ACID MOLECULA THAT CODIFIES IT; VECTOR AND CELL GUESTS THAT UNDERSTAND IT; CONJUGADO UNDERSTANDING THE AGENT; AND USE OF THE AGENT OF A
|
EP2054437A2
(en)
|
2006-08-07 |
2009-05-06 |
Teva Biopharmaceuticals USA, Inc. |
Albumin-insulin fusion proteins
|
EP2615108B1
(en)
|
2006-09-08 |
2016-10-26 |
Ambrx, Inc. |
Modified human plasma polypeptide or fc scaffolds and thier uses
|
US7767206B2
(en)
|
2006-10-02 |
2010-08-03 |
Amgen Inc. |
Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
|
MX2009004757A
(en)
|
2006-11-14 |
2009-05-21 |
Genentech Inc |
Modulators of neuronal regeneration.
|
PT2121751T
(en)
|
2006-12-08 |
2017-04-18 |
Lexicon Pharmaceuticals Inc |
Monoclonal antibodies against angptl3
|
TWI428346B
(en)
|
2006-12-13 |
2014-03-01 |
Imp Innovations Ltd |
Novel compounds and their effects on feeding behaviour
|
RU2554747C9
(en)
|
2006-12-20 |
2015-10-20 |
Ксома (Сша) Ллс |
Method of treating il-1beta-dependent diseases
|
DK2740744T3
(en)
|
2007-01-09 |
2018-04-23 |
Biogen Ma Inc |
Sp35 antibodies and uses thereof
|
TWI438208B
(en)
|
2007-01-23 |
2014-05-21 |
Chugai Pharmaceutical Co Ltd |
Agents for suppressing chronic rejection reaction
|
GEP20135853B
(en)
|
2007-02-02 |
2013-06-25 |
Univ Pierre And Marie Curie |
Method of myelination and oligodendrocyte differentiation promotion
|
US8501678B2
(en)
|
2007-03-06 |
2013-08-06 |
Atara Biotherapeutics, Inc. |
Variant activin receptor polypeptides and uses thereof
|
US7947646B2
(en)
|
2007-03-06 |
2011-05-24 |
Amgen Inc. |
Variant activin receptor polypeptides
|
CL2008000719A1
(en)
|
2007-03-12 |
2008-09-05 |
Univ Tokushima Chugai Seiyaku |
THERAPEUTIC AGENT FOR CANCER RESISTANT TO CHEMOTHERAPEUTIC AGENTS THAT UNDERSTAND AN ANTIBODY THAT RECOGNIZES IT CLASS I AS ACTIVE INGREDIENT; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH ANTIBODY; AND METHOD TO TREAT CANCER RESISTANT TO
|
ATE554785T1
(en)
|
2007-03-30 |
2012-05-15 |
Ambrx Inc |
MODIFIED FGF-21 POLYPEPTIDES AND THEIR USE
|
WO2008140026A1
(en)
|
2007-05-11 |
2008-11-20 |
Bizen Chemical Co., Ltd. |
Novel leukotriene receptor antagonist
|
EP1995227A1
(en)
|
2007-05-24 |
2008-11-26 |
Chevron USA, Inc. |
Spiro and other derivatives of diamondoids posessing therapeutic activity in the treatment of viral disorders
|
EP1994927A1
(en)
|
2007-05-24 |
2008-11-26 |
Chevron USA, Inc. |
Diamondoid derivatives possessing therapeutic activity in the treatment of viral disorders
|
MX2009013765A
(en)
|
2007-06-27 |
2010-02-01 |
Auckland Uniservices Ltd |
Polypeptides and polynucleotides for artemin and related ligands, and methods of use thereof.
|
EP2174667B1
(en)
|
2007-07-26 |
2017-01-04 |
Osaka University |
Agent for treatment of ophthalmia containing interleukin-6 receptor inhibitor as active ingredient
|
CL2008002444A1
(en)
|
2007-08-21 |
2009-09-04 |
Amgen Inc |
Antibody or fragment thereof that binds to human c-fms protein; nucleic acid molecule that encodes it; vector and host cell; production method; pharmaceutical composition comprising it; and its use to treat or prevent a condition associated with c-fms in a patient.
|
JOP20080381B1
(en)
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
Antigen Binding Proteins to Proprotein Convertase subtillisin Kexin type 9 (pcsk9)
|
EP2615114B1
(en)
|
2007-08-23 |
2022-04-06 |
Amgen Inc. |
Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
|
US7982016B2
(en)
|
2007-09-10 |
2011-07-19 |
Amgen Inc. |
Antigen binding proteins capable of binding thymic stromal lymphopoietin
|
US20090156488A1
(en)
|
2007-09-12 |
2009-06-18 |
Zensun (Shanghai) Science & Technology Limited |
Use of neuregulin for organ preservation
|
TW200918553A
(en)
|
2007-09-18 |
2009-05-01 |
Amgen Inc |
Human GM-CSF antigen binding proteins
|
EP2040075A1
(en)
|
2007-09-24 |
2009-03-25 |
Julius-Maximilians-Universität Würzburg |
Compounds and markers for surface-enhanced raman scattering
|
MX2010003380A
(en)
|
2007-09-26 |
2010-10-15 |
U3 Pharma Gmbh |
Heparin-binding epidermal growth factor-like growth factor antigen binding proteins.
|
EP2196220B1
(en)
|
2007-10-02 |
2014-12-03 |
Chugai Seiyaku Kabushiki Kaisha |
Inhibting anti-IL-6 receptor antibody for treating graft-versus-host disease
|
ME01026B
(en)
|
2007-11-16 |
2012-10-20 |
Univ Rockefeller |
Antibodies specific for the protofibril form of beta-amyloid protein
|
EP2930182A1
(en)
|
2007-11-20 |
2015-10-14 |
Ambrx, Inc. |
Modified insulin polypeptides and their uses
|
BRPI0821110B8
(en)
|
2007-12-05 |
2021-05-25 |
Chugai Pharmaceutical Co Ltd |
anti-nr10/il31ra neutralizing antibody, pharmaceutical composition comprising said antibody and use thereof
|
MY185647A
(en)
|
2007-12-05 |
2021-05-27 |
Chugai Pharmaceutical Co Ltd |
Therapeutic agent for pruritus
|
US20110262425A1
(en)
|
2007-12-12 |
2011-10-27 |
National Cancer Center |
Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
|
PT2391650E
(en)
|
2007-12-20 |
2015-01-14 |
Xoma Us Llc |
Methods for the treatment of gout
|
SG188143A1
(en)
|
2008-02-08 |
2013-03-28 |
Ambrx Inc |
Modified leptin polypeptides and their uses
|
JO2913B1
(en)
|
2008-02-20 |
2015-09-15 |
امجين إنك, |
Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
|
JOP20190083A1
(en)
|
2008-06-04 |
2017-06-16 |
Amgen Inc |
Fgf21 mutant fusion polypeptides and uses thereof
|
CA2728243C
(en)
|
2008-06-05 |
2020-03-10 |
National Cancer Center |
Il-6 inhibitor for suppressing neuroinvasion in pancreatic cancer
|
EP2307381B1
(en)
|
2008-06-09 |
2021-01-13 |
Ludwig-Maximilians-Universität München |
New drugs for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases
|
EP2671891A3
(en)
|
2008-06-27 |
2014-03-05 |
Amgen Inc. |
Ang-2 inhibition to treat multiple sclerosis
|
DK2982695T3
(en)
|
2008-07-09 |
2019-05-13 |
Biogen Ma Inc |
COMPOSITIONS CONCERNING ANTIBODIES AGAINST LINGO OR FRAGMENTS THEREOF
|
US10138283B2
(en)
|
2008-07-23 |
2018-11-27 |
Ambrx, Inc. |
Modified bovine G-CSF polypeptides and their uses
|
KR20110051245A
(en)
|
2008-09-10 |
2011-05-17 |
제넨테크, 인크. |
Methods for inhibiting ocular angiogenesis
|
EP2927244A1
(en)
|
2008-09-19 |
2015-10-07 |
MedImmune, LLC |
Antibodies directed to DLL4 and uses thereof
|
MX2011003196A
(en)
|
2008-09-26 |
2011-04-27 |
Ambrx Inc |
Non-natural amino acid replication-dependent microorganisms and vaccines.
|
CN102232085A
(en)
|
2008-09-26 |
2011-11-02 |
Ambrx公司 |
Modified animal erythropoietin polypeptides and their uses
|
EA032727B1
(en)
|
2008-10-10 |
2019-07-31 |
Амген Инк. |
Fgf21 mutant proteolysis-resistant polypeptide and use thereof
|
JP2012504969A
(en)
|
2008-10-10 |
2012-03-01 |
アナフォア インコーポレイテッド |
Polypeptides that bind to TRAIL-R1 and TRAIL-R2
|
AU2009308293B2
(en)
|
2008-10-22 |
2015-02-05 |
Genentech, Inc. |
Modulation of axon degeneration
|
PE20120206A1
(en)
|
2008-11-26 |
2012-03-09 |
Amgen Inc |
ACTIVIN IIB RECEPTOR POLYPEPTIDE VARIANTS
|
US20120087870A1
(en)
|
2008-12-19 |
2012-04-12 |
Hentges Francois |
Novel caviidae allergens and uses thereof
|
WO2010072684A1
(en)
|
2008-12-22 |
2010-07-01 |
Universität Regensburg |
Norrin in the treatment of diseases associated with an increased tgf-beta activity
|
JO3382B1
(en)
|
2008-12-23 |
2019-03-13 |
Amgen Inc |
Human cgrp receptor binding antibodies
|
EP2379595A2
(en)
|
2008-12-23 |
2011-10-26 |
AstraZeneca AB |
Targeted binding agents directed to 5 1 and uses thereof
|
US9139809B2
(en)
|
2009-01-08 |
2015-09-22 |
Albert Einstein College Of Medicine Of Yeshiva University |
Bacterial vaccines with cell wall-associated ceramide-like glycolipids and uses thereof
|
US20110294733A1
(en)
|
2009-01-20 |
2011-12-01 |
Hanall Biopharma Co., Ltd. |
Modified human thrombopoietin polypeptide fragment and manufacturing method thereof
|
EP2396035A4
(en)
|
2009-02-12 |
2012-09-12 |
Human Genome Sciences Inc |
Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
|
CN102369211B
(en)
|
2009-02-13 |
2015-04-29 |
诺华股份有限公司 |
Nucleic acid molecule of a biosynthetic cluster encoding non ribosomal peptide synthases and uses thereof
|
KR20110136819A
(en)
|
2009-02-27 |
2011-12-21 |
시가 테크놀로지스, 인크. |
Thienopyridine derivatives for the treatment and prevention of dengue virus infections
|
JP2010210772A
(en)
|
2009-03-13 |
2010-09-24 |
Dainippon Screen Mfg Co Ltd |
Method of manufacturing liquid crystal display device
|
US9724337B2
(en)
|
2009-04-21 |
2017-08-08 |
University Of Kentucky Research Foundation |
AG-205 for the treatment of breast cancer
|
HRP20240135T1
(en)
|
2009-05-05 |
2024-04-12 |
Amgen Inc. |
Fgf21 mutants and uses thereof
|
US20120052069A1
(en)
|
2009-05-05 |
2012-03-01 |
Amgen Inc |
Fgf21 mutants and uses thereof
|
EP2260857A1
(en)
|
2009-06-11 |
2010-12-15 |
Alfact Innovation |
Novel applications of HIP/PAP or derivatives thereof
|
IN2012DN00352A
(en)
|
2009-06-16 |
2015-08-21 |
Bikam Pharmaceuticals Inc |
|
WO2010148142A1
(en)
|
2009-06-17 |
2010-12-23 |
Amgen Inc. |
Chimeric fgf19 polypeptides and uses thereof
|
SG10201404340TA
(en)
|
2009-07-31 |
2014-10-30 |
Shin Maeda |
Cancer metastasis inhibitor
|
TW201118166A
(en)
|
2009-09-24 |
2011-06-01 |
Chugai Pharmaceutical Co Ltd |
HLA class I-recognizing antibodies
|
EP2305285A1
(en)
|
2009-09-29 |
2011-04-06 |
Julius-Maximilians-Universität Würzburg |
Means and methods for treating ischemic conditions
|
EP2305810A1
(en)
|
2009-10-02 |
2011-04-06 |
Technische Universität München |
miRNAs in the treatment of fibrosis
|
TW201117824A
(en)
|
2009-10-12 |
2011-06-01 |
Amgen Inc |
Use of IL-17 receptor a antigen binding proteins
|
CN102711772A
(en)
|
2009-10-16 |
2012-10-03 |
奥克兰联合服务有限公司 |
Anti-neoplastic uses of artemin antagonists
|
US9068019B2
(en)
|
2009-10-19 |
2015-06-30 |
Hanall Biopharma Co., Ltd. |
Modified human tumor necrosis factor receptor-1 polypeptide or fragment thereof, and method for preparing same
|
CN104043126A
(en)
|
2009-10-22 |
2014-09-17 |
霍夫曼-拉罗奇有限公司 |
Modulation of axon degeneration
|
BR112012010202A2
(en)
|
2009-11-02 |
2015-09-22 |
Univ Washington |
dimeric polypeptide hybrid nuclease molecule, pharmaceutical composition nucleic acid molecule recombinant expression vector transformed host cell method for preparing the nuclease molecule and method for treating or preventing a condition associated with an abnormal immune
|
EP2742949A1
(en)
|
2009-11-13 |
2014-06-18 |
Puget Sound Blood Center |
Factor VIII B cell epitope variants having reduced immunogenicity
|
NZ599405A
(en)
|
2009-11-24 |
2014-09-26 |
Medimmune Ltd |
Targeted binding agents against b7-h1
|
US8491927B2
(en)
|
2009-12-02 |
2013-07-23 |
Nimble Epitech, Llc |
Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
|
JP2013512672A
(en)
|
2009-12-02 |
2013-04-18 |
アムジエン・インコーポレーテツド |
Human FGFR1c, human β-croto-, and binding proteins that bind to both human FGFR1c and human β-croto-
|
UA109888C2
(en)
|
2009-12-07 |
2015-10-26 |
|
ANTIBODY OR ANTIBODILITY ANTIBODY OR ITS BINDING TO THE β-CLOTE, FGF RECEPTORS AND THEIR COMPLEXES
|
MX349301B
(en)
|
2009-12-21 |
2017-07-21 |
Ambrx Inc |
Modified bovine somatotropin polypeptides and their uses.
|
BR112012015597A2
(en)
|
2009-12-21 |
2017-01-31 |
Ambrx Inc |
modified porcine somatotropin peptides and their uses
|
EP2525792A1
(en)
|
2010-01-19 |
2012-11-28 |
Medizinische Universität Wien |
Pharmaceutical compositions comprising lignans and their derivatives for the medical management of angiogenesis and hypovascularity
|
JP6046493B2
(en)
|
2010-01-27 |
2016-12-14 |
チルドレンズ メディカル センター コーポレーション |
Proangin-1 angiogenesis-promoting fragments and uses thereof
|
EP2533859B1
(en)
|
2010-02-10 |
2016-04-06 |
Nayacure Therapeutics Ltd |
Pharmaceutical compositions for the treatment and prevention of cancer
|
US9233087B2
(en)
|
2010-02-19 |
2016-01-12 |
Siga Technologies, Inc |
Inhibitors and methods of inhibiting bacterial and viral pathogens
|
WO2011119906A1
(en)
|
2010-03-26 |
2011-09-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
HUMAN POLYOMAVIRUS 6 (HPyV6) AND HUMAN POLYOMAVIRUS 7 (HPyV7)
|
JPWO2011118804A1
(en)
|
2010-03-26 |
2013-07-04 |
国立大学法人徳島大学 |
Novel anti-CD98 antibody and its use
|
AU2011239689A1
(en)
|
2010-04-15 |
2012-11-08 |
Amgen Inc. |
Human FGF receptor and beta-Klotho binding proteins
|
US20130116304A1
(en)
|
2010-04-19 |
2013-05-09 |
Ernst R. Werner |
Tmem195 encodes for tetrahydrobiopterin-dependent alkylglycerol monooxygenase activity
|
WO2011139594A2
(en)
|
2010-04-27 |
2011-11-10 |
Medtronic, Inc. |
Artificial bursa for intra-articular drug delivery
|
WO2011139595A2
(en)
|
2010-04-27 |
2011-11-10 |
Medtronic, Inc. |
Elongated biodegradable depot for sustained drug release to treat chronic pelvic pain
|
EP3181692A1
(en)
|
2010-05-07 |
2017-06-21 |
Centre National De La Recherche Scientifique |
Ucp1 (thermogenin) - inducing agents for use in the treatment of a disorder of the energy homeostasis
|
CA2800065A1
(en)
|
2010-05-21 |
2011-11-24 |
Peptimed, Inc. |
Reagents and methods for treating cancer
|
EP4115906A1
(en)
|
2010-05-28 |
2023-01-11 |
Chugai Seiyaku Kabushiki Kaisha |
Antitumor t cell response enhancer
|
JP5904552B2
(en)
|
2010-05-28 |
2016-04-13 |
国立研究開発法人国立がん研究センター |
Pancreatic cancer treatment
|
ES2486321T3
(en)
|
2010-06-18 |
2014-08-18 |
Xiberscience Gmbh |
Peptides as active agents to stabilize biological barriers
|
HUE045845T2
(en)
|
2010-08-17 |
2021-12-28 |
Ambrx Inc |
Modified relaxin polypeptides and their uses
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
AR083006A1
(en)
|
2010-09-23 |
2013-01-23 |
Lilly Co Eli |
FORMULATIONS FOR THE STIMULATING FACTOR OF COLONIES OF GRANULOCITS (G-CSF) BOVINE AND VARIANTS OF THE SAME
|
EP2623592B1
(en)
|
2010-09-28 |
2019-05-15 |
NB Health Laboratory Co. Ltd. |
Anti-human ccr7 antibodies, hybridoma, medicinal composition, and antibody-immobilized carrier
|
EP2632481A1
(en)
|
2010-10-25 |
2013-09-04 |
Regents Of The University Of Minnesota |
Therapeutic composition for treatment of glioblastoma
|
TWI636994B
(en)
|
2010-10-27 |
2018-10-01 |
安美基公司 |
Dkk1 antibodies and methods of use
|
AU2011323508B2
(en)
|
2010-11-01 |
2017-04-27 |
Peptimed, Inc. |
Compositions of a peptide targeting system for treating cancer
|
TR201802772T4
(en)
|
2010-11-17 |
2018-03-21 |
Chugai Pharmaceutical Co Ltd |
Multi-specific antigen binding molecule with alternative function for the function of blood coagulation factor VIII.
|
US9023791B2
(en)
|
2010-11-19 |
2015-05-05 |
Novartis Ag |
Fibroblast growth factor 21 mutations
|
RU2013123793A
(en)
|
2010-11-24 |
2014-12-27 |
Лексикон Фармасьютикалз, Инк. |
ANTIBODIES RELATING TO NOTUM PECTINACETHYLESTERASE
|
CA2819501C
(en)
|
2010-11-30 |
2020-03-31 |
The Johns Hopkins University |
Hybrid cyclic libraries and screens thereof
|
AR084053A1
(en)
|
2010-11-30 |
2013-04-17 |
Chugai Pharmaceutical Co Ltd |
THERAPEUTIC AGENT THAT INDUCES CYTOTOXICITY
|
DK2657252T3
(en)
|
2010-12-23 |
2017-05-08 |
Hanall Biopharma Co Ltd |
MODIFIED HUMAN TUMOR CANCER FACTOR RECEPTOR-1 POLYPEPTIDE OR FRAGMENT THEREOF AND METHOD OF PRODUCING THEREOF
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
WO2012102679A1
(en)
|
2011-01-24 |
2012-08-02 |
National University Of Singapore |
Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
|
EP2667715B1
(en)
|
2011-01-27 |
2017-07-19 |
Neuren Pharmaceuticals Limited |
Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glutamic acid
|
WO2012118903A2
(en)
|
2011-03-01 |
2012-09-07 |
Amgen Inc. |
Bispecific binding agents
|
RU2013141611A
(en)
|
2011-03-10 |
2015-04-20 |
Дженентек, Инк. |
TREATMENT OF DISEASES WITH AN CHANGED VASCULAR FUNCTION OF VESSELS
|
KR20140027211A
(en)
|
2011-04-04 |
2014-03-06 |
유니버시티 오브 아이오와 리써치 파운데이션 |
Methods of improving vaccine immunogenicity
|
CN103619881B
(en)
|
2011-04-07 |
2017-07-28 |
安姆根有限公司 |
New EGFR associated proteins
|
CN103533951B
(en)
|
2011-04-08 |
2017-04-19 |
安姆根有限公司 |
Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15)
|
PL2704737T3
(en)
|
2011-04-29 |
2018-07-31 |
University Of Washington |
Therapeutic nuclease compositions and methods
|
JP2014513128A
(en)
|
2011-05-03 |
2014-05-29 |
ジェネンテック, インコーポレイテッド |
Vascular disruptors and their use
|
JOP20200043A1
(en)
|
2011-05-10 |
2017-06-16 |
Amgen Inc |
Methods of treating or preventing cholesterol related disorders
|
EP2707718A1
(en)
|
2011-05-10 |
2014-03-19 |
Amgen Inc. |
Method of identifying compounds that specifically modulate the interaction of fgfr1 and beta-klotho
|
US9574002B2
(en)
|
2011-06-06 |
2017-02-21 |
Amgen Inc. |
Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
|
EA032666B1
(en)
|
2011-06-14 |
2019-06-28 |
Бикам Фармасьютикалз, Инк. |
Opsin-binding ligands and methods of use thereof
|
CA2838340A1
(en)
|
2011-06-17 |
2012-12-20 |
Amgen Inc. |
Method of treating or ameliorating metabolic disorders using clec-2
|
US20140234330A1
(en)
|
2011-07-22 |
2014-08-21 |
Amgen Inc. |
Il-17 receptor a is required for il-17c biology
|
WO2013017656A1
(en)
|
2011-08-02 |
2013-02-07 |
Medizinische Universität Wien |
Antagonists of ribonucleases for treating obesity
|
CA2843369A1
(en)
|
2011-08-16 |
2013-02-21 |
Evotec (Munchen) Gmbh |
Markers for susceptibility to an inhibitor of an src-family kinase
|
US9745288B2
(en)
|
2011-08-16 |
2017-08-29 |
Indiana University Research And Technology Corporation |
Compounds and methods for treating cancer by inhibiting the urokinase receptor
|
EP2744828A4
(en)
|
2011-08-16 |
2014-12-31 |
Univ Emory |
Jaml specific binding agents, antibodies, and uses related thereto
|
US20140213512A1
(en)
|
2011-08-31 |
2014-07-31 |
Amgen Inc. |
Method of Treating or Ameliorating Type 1 Diabetes Using FGF21
|
WO2013039916A1
(en)
|
2011-09-12 |
2013-03-21 |
The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services |
Compositions for and methods of treatment and enhanced detection of non-pituitary tumors
|
MX353958B
(en)
|
2011-09-22 |
2018-02-07 |
Amgen Inc |
Cd27l antigen binding proteins.
|
TW201315742A
(en)
|
2011-09-26 |
2013-04-16 |
Novartis Ag |
Dual fuction proteins for treating metabolic disorders
|
US9006400B2
(en)
|
2011-09-26 |
2015-04-14 |
Novartis Ag |
Fibroblast growth factor-21-Fc fusion proteins
|
KR102239138B1
(en)
|
2011-09-30 |
2021-04-12 |
추가이 세이야쿠 가부시키가이샤 |
Antigen-binding molecule inducing immune response to target antigen
|
WO2013053076A1
(en)
|
2011-10-10 |
2013-04-18 |
Zensun (Shanghai)Science & Technology Limited |
Compositions and methods for treating heart failure
|
US8906860B2
(en)
|
2011-10-14 |
2014-12-09 |
The Board Of Trustees Of The University Of Illinois |
Methods and compositions inhibiting tumor cell proliferation
|
WO2013056255A1
(en)
|
2011-10-14 |
2013-04-18 |
The Board Of Trustees Of The University Of Illinois |
Methods and compositions for inhibiting tumor cell proliferation
|
EP2768307B1
(en)
|
2011-10-19 |
2020-03-18 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
AU2012340174A1
(en)
|
2011-11-16 |
2014-05-29 |
Amgen Inc. |
Methods of treating epidermal growth factor deletion mutant VIII related disorders
|
GR1007832B
(en)
|
2011-11-21 |
2013-02-14 |
Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, |
Activin neutralisers and uses thereof for treatment of diseases associated with aberrant "host defence response" activation
|
US9353063B2
(en)
|
2011-11-30 |
2016-05-31 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
CA2862746A1
(en)
|
2011-12-01 |
2013-06-06 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
EP2601941A1
(en)
|
2011-12-06 |
2013-06-12 |
Ludwig-Maximilians-Universität München |
Beta-O/S/N fatty acid based compounds as antibacterial and antiprotozoal agents
|
CA2858572C
(en)
|
2011-12-08 |
2023-01-17 |
Amgen Inc. |
Human lcat antigen binding proteins and their use in therapy
|
WO2013083810A1
(en)
|
2011-12-09 |
2013-06-13 |
F. Hoffmann-La Roche Ag |
Identification of non-responders to her2 inhibitors
|
SG11201403367YA
(en)
|
2011-12-19 |
2014-07-30 |
Amgen Inc |
Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
|
US20150017157A1
(en)
|
2011-12-19 |
2015-01-15 |
Xoma (Us) Llc |
Methods for treating acne
|
WO2013106489A1
(en)
|
2012-01-09 |
2013-07-18 |
The Scripps Research Institute |
Humanized antibodies with ultralong cdr3s
|
WO2013106485A2
(en)
|
2012-01-09 |
2013-07-18 |
The Scripps Research Institute |
Ultralong complementarity determining regions and uses thereof
|
US9512212B2
(en)
|
2012-01-11 |
2016-12-06 |
Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University |
Bispecific antibody fragments for neurological disease proteins and methods of use
|
US9714276B2
(en)
|
2012-01-26 |
2017-07-25 |
Amgen Inc. |
Growth differentiation factor 15 (GDF-15) polypeptides
|
EP2626066A1
(en)
|
2012-02-10 |
2013-08-14 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Combination therapy comprising selective VEGFR-2 inhibitors and MEK inhibitors
|
AU2013221475B2
(en)
|
2012-02-17 |
2016-10-20 |
Kineta Four Llc |
Antiviral drugs for treatment of Arenavirus infection
|
US9879012B2
(en)
|
2012-03-29 |
2018-01-30 |
Regents Of The University Of Colorado, A Body Corporate |
Click nucleic acids
|
US20150118237A1
(en)
|
2012-04-23 |
2015-04-30 |
Genefrontier Corporation |
Anti-human cd69 antibody, and use thereof for medical purposes
|
EA039663B1
(en)
|
2012-05-03 |
2022-02-24 |
Амген Инк. |
Use of an anti-pcsk9 antibody for lowering serum cholesterol ldl and treating cholesterol related disorders
|
JO3623B1
(en)
|
2012-05-18 |
2020-08-27 |
Amgen Inc |
St2 antigen binding proteins
|
EP2666775A1
(en)
|
2012-05-21 |
2013-11-27 |
Domain Therapeutics |
Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
|
US9844582B2
(en)
|
2012-05-22 |
2017-12-19 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
|
EP2852584B1
(en)
|
2012-05-22 |
2018-02-28 |
F. Hoffmann-La Roche AG |
Substituted dipyridylamines and uses thereof
|
MX2014014234A
(en)
|
2012-05-22 |
2015-05-07 |
Genentech Inc |
N-substituted benzamides and their use in the treatment of pain.
|
AU2013285537B2
(en)
|
2012-07-02 |
2017-10-12 |
Medizinische Universitat Wien |
Complement split product C4d for the treatment of inflammatory conditions
|
CA2878478A1
(en)
|
2012-07-06 |
2014-01-09 |
Genentech, Inc. |
N-substituted benzamides and methods of use thereof
|
EP2687225A1
(en)
|
2012-07-19 |
2014-01-22 |
Alfact Innovation |
HIP/PAP protein and derivatives thereof for use in treating cancer
|
EP2695950A1
(en)
|
2012-08-10 |
2014-02-12 |
Blackfield AG |
Markers for responsiveness to an inhibitor of the fibroblast growth factor receptor
|
EP2887942A4
(en)
|
2012-08-21 |
2016-08-31 |
Genesys Res Inst |
Compositions and methods for treating or preventing anthracycline induced cardiotoxicity
|
BR112015006737A2
(en)
|
2012-09-27 |
2017-07-04 |
Hoffmann La Roche |
substituted sulfonamide compounds
|
JP6336459B2
(en)
|
2012-10-17 |
2018-06-06 |
バスキュラー バイオジェニックス リミテッド |
Treatment method using adenovirus
|
US9309318B2
(en)
|
2012-10-17 |
2016-04-12 |
Amgen, Inc. |
Compositions relating to anti-IL-21 receptor antibodies
|
CN108424453B
(en)
|
2012-11-09 |
2021-08-06 |
基因先端领域株式会社 |
anti-ADAM 28 antibodies for the treatment of cancer
|
UY35148A
(en)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
HETERODIMERIC IMMUNOGLOBULINS
|
MX363188B
(en)
|
2012-11-30 |
2019-03-13 |
Hoffmann La Roche |
Identification of patients in need of pd-l1 inhibitor cotherapy.
|
TW201425336A
(en)
|
2012-12-07 |
2014-07-01 |
Amgen Inc |
BCMA antigen binding proteins
|
BR112015016395A2
(en)
|
2013-01-18 |
2017-07-11 |
Hoffmann La Roche |
3-substituted pyrazoles and use as dlk inhibitors
|
ES2728936T3
(en)
|
2013-01-25 |
2019-10-29 |
Amgen Inc |
Antibodies directed against CDH19 for melanoma
|
JO3519B1
(en)
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
Antibody constructs for CDH19 and CD3
|
MX2015009901A
(en)
|
2013-02-01 |
2016-04-06 |
Santa Maria Biotherapeutics Inc |
Administration of an anti-activin-a compound to a subject.
|
US9371352B2
(en)
|
2013-02-08 |
2016-06-21 |
Vaccinex, Inc. |
Modified glycolipids and methods of making and using the same
|
US9458246B2
(en)
|
2013-03-13 |
2016-10-04 |
Amgen Inc. |
Proteins specific for BAFF and B7RP1
|
JOP20140087B1
(en)
|
2013-03-13 |
2021-08-17 |
Amgen Inc |
Proteins specific for baff and b7rp1 and uses thereof
|
WO2014153037A1
(en)
|
2013-03-14 |
2014-09-25 |
Genentech, Inc. |
Substituted triazolopyridines and methods of use thereof
|
US20140271629A1
(en)
|
2013-03-14 |
2014-09-18 |
Amgen Inc. |
Chrdl-1 antigen binding proteins and methods of treatment
|
US9580486B2
(en)
|
2013-03-14 |
2017-02-28 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of T-regulatory cells
|
US9850297B2
(en)
|
2013-03-15 |
2017-12-26 |
Amgen Inc. |
Secreted frizzle-related protein 5 (SFRP5) binding proteins
|
AU2014236867A1
(en)
|
2013-03-15 |
2015-09-24 |
Amgen Inc. |
Methods and compositions relating to anti-CCR7 antigen binding proteins
|
AP2015008732A0
(en)
|
2013-03-15 |
2015-09-30 |
Amgen Inc |
Human pac1 antibodies
|
AR095596A1
(en)
|
2013-03-15 |
2015-10-28 |
Amgen Res (Munich) Gmbh |
UNIQUE CHAIN UNION MOLECULES UNDERSTANDING N-TERMINAL ABP
|
US9708375B2
(en)
|
2013-03-15 |
2017-07-18 |
Amgen Inc. |
Inhibitory polypeptides specific to WNT inhibitors
|
US9505849B2
(en)
|
2013-03-15 |
2016-11-29 |
Amgen Research (Munich) Gmbh |
Antibody constructs for influenza M2 and CD3
|
US9474792B2
(en)
|
2013-03-15 |
2016-10-25 |
Amgen Inc. |
Method of treating metabolic disorders using PLA2G12A polypeptides and PLA2G12A mutant polypeptides
|
CN105164114B
(en)
|
2013-05-01 |
2018-03-23 |
豪夫迈·罗氏有限公司 |
The miazines and their purposes of the Heterocyclylalkyl substitution of C connections
|
CN110003178B
(en)
|
2013-05-01 |
2022-02-25 |
豪夫迈·罗氏有限公司 |
Diheteroaryl compounds and uses thereof
|
US10501803B2
(en)
|
2013-05-21 |
2019-12-10 |
Max-Planck Gesellschaft zur Förderung der Wissenschaften e.V. |
Isoforms of GATA6 and NKX2-1 as markers for diagnosis and therapy of cancer and as targets for anti-cancer therapy
|
BR112015029293A2
(en)
|
2013-05-22 |
2018-04-24 |
Zensun Shanghai Science & Tech Ltd |
method and kit for preventing, treating or delaying a cardiovascular disease or disorder in a mammal
|
US20160130585A1
(en)
|
2013-05-28 |
2016-05-12 |
The Johns Hopkins University |
Aptamers for the treatment of sickle cell disease
|
EA201592285A1
(en)
|
2013-05-30 |
2016-05-31 |
Байоджен Ма Инк. |
ANTIGENSYCLING PROTEINS TO ONCOSTATIN M RECEPTOR
|
EP2810648A1
(en)
|
2013-06-04 |
2014-12-10 |
Daniel Rauh |
Targeting domain-domain interaction for the identification of kinase modulators
|
EP3009518B1
(en)
|
2013-06-11 |
2020-08-12 |
National Center of Neurology and Psychiatry |
Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (rrms) patient, and method for determining applicability of novel therapy
|
EP2835135A3
(en)
|
2013-06-19 |
2015-06-24 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin |
Means and methods for treating pseudomonas infection
|
WO2014207213A1
(en)
|
2013-06-28 |
2014-12-31 |
Medizinische Universität Innsbruck |
Novel inhibitors of protein kinase c epsilon signaling
|
AU2013396206B2
(en)
|
2013-06-28 |
2019-11-14 |
Amgen Inc. |
Methods for treating homozygous familial hypercholesterolemia
|
EP3693397A1
(en)
|
2013-07-11 |
2020-08-12 |
The Scripps Research Institute |
Coiled coil immunoglobulin fusion proteins and compositions thereof
|
EP3022224A2
(en)
|
2013-07-18 |
2016-05-25 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
EA202092386A1
(en)
|
2013-07-31 |
2021-04-30 |
Эмджен Инк. |
CONSTRUCTIONS BASED ON DIFFERENTIATION AND GROWTH FACTOR 15 (GDF15)
|
WO2015022326A1
(en)
|
2013-08-12 |
2015-02-19 |
Xiber Science Gmbh |
Peptides as active agents for treating primary graft dysfunction
|
TW201605896A
(en)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
GITR antigen binding proteins
|
EP3712166A1
(en)
|
2013-09-05 |
2020-09-23 |
Amgen Inc. |
Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
|
CA2923835C
(en)
|
2013-09-11 |
2022-11-29 |
The Administrators Of The Tulane Educational Fund |
Novel anthranilic amides and the use thereof
|
AR097648A1
(en)
|
2013-09-13 |
2016-04-06 |
Amgen Inc |
COMBINATION OF EPIGENETIC FACTORS AND BIESPECTIVE COMPOUNDS THAT HAVE LIKE DIANA CD33 AND CD3 IN THE TREATMENT OF MYELOID LEUKEMIA
|
WO2015038938A1
(en)
|
2013-09-13 |
2015-03-19 |
The California Institute For Biomedical Research |
Modified therapeutic agents and compositions thereof
|
AU2014320262B2
(en)
|
2013-09-16 |
2019-06-13 |
Cemm - Forschungszentrum Fur Molekulare Medizin Gmbh |
Mutant calreticulin for the diagnosis of myeloid malignancies
|
JP6445440B2
(en)
|
2013-09-20 |
2018-12-26 |
中外製薬株式会社 |
Treatment of bleeding disorders with anti-protein C antibodies
|
DK3049521T3
(en)
|
2013-09-25 |
2019-04-23 |
Univ Cornell |
Compounds for inducing antitumor immunity and methods thereof
|
DK3052102T3
(en)
|
2013-10-04 |
2020-03-09 |
Aptose Biosciences Inc |
CANCER TREATMENT COMPOSITIONS
|
PL3055302T3
(en)
|
2013-10-11 |
2019-05-31 |
Hoffmann La Roche |
Substituted heterocyclic sulfonamide compounds useful as trpa1 modulators
|
CA2927525C
(en)
|
2013-10-15 |
2023-01-31 |
Genefrontier Corporation |
Human antibody against aggrecanase-type adamts species for therapeutics of aggrecanase-related diseases
|
US20150238631A1
(en)
|
2013-10-15 |
2015-08-27 |
The California Institute For Biomedical Research |
Chimeric antigen receptor t cell switches and uses thereof
|
KR102339240B1
(en)
|
2013-10-15 |
2021-12-15 |
더 스크립스 리서치 인스티튜트 |
Peptidic chimeric antigen receptor t cell switches and uses thereof
|
EP3057605A1
(en)
|
2013-10-18 |
2016-08-24 |
Novartis AG |
Methods of treating diabetes and related disorders
|
US10988745B2
(en)
|
2013-10-31 |
2021-04-27 |
Resolve Therapeutics, Llc |
Therapeutic nuclease-albumin fusions and methods
|
EP4212180A1
(en)
|
2013-12-18 |
2023-07-19 |
The Scripps Research Institute |
Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
|
MX2016008110A
(en)
|
2013-12-20 |
2016-08-19 |
Hoffmann La Roche |
Pyrazole derivatives and uses thereof as inhibitors of dlk.
|
CN103965357B
(en)
|
2013-12-31 |
2016-08-17 |
嘉和生物药业有限公司 |
A kind of anti-human RANKL antibody
|
WO2015110930A1
(en)
|
2014-01-24 |
2015-07-30 |
Pfizer Inc. |
Modified interleukin 21 receptor proteins
|
WO2015120187A1
(en)
|
2014-02-05 |
2015-08-13 |
The University Of Chicago |
Chimeric antigen receptors recognizing cancer-spevific tn glycopeptide variants
|
WO2015121457A1
(en)
|
2014-02-13 |
2015-08-20 |
Westphal Sören |
Fgf-8 for use in treating diseases or disorders of energy homeostasis
|
US9701743B2
(en)
|
2014-02-20 |
2017-07-11 |
Allergan, Inc. |
Complement component C5 antibodies
|
JP6643244B2
(en)
|
2014-02-27 |
2020-02-12 |
アラーガン、インコーポレイテッドAllergan,Incorporated |
Complement factor Bb antibody
|
CA2941716A1
(en)
|
2014-03-07 |
2015-09-11 |
The Johns Hopkins University |
Inhibitors of histone lysine specific demethylase (lsd1) and histone deacetylases (hdacs)
|
US10507227B2
(en)
|
2014-04-15 |
2019-12-17 |
The Hospital For Sick Children |
Cationic antimicrobial peptides
|
EP3143143A1
(en)
|
2014-05-15 |
2017-03-22 |
CeMM - Forschungszentrum für Molekulare Medizin GmbH |
Antagonists of slc38a9 and their use in therapy
|
WO2015179415A1
(en)
|
2014-05-19 |
2015-11-26 |
Novartis Ag |
Methods of treating anorexia
|
EP2947460A1
(en)
|
2014-05-22 |
2015-11-25 |
Medizinische Universität Wien |
Personalized therapy of inflammation-associated cancer using methods of assessing the susceptibility of a subject to the treatment with EGFR inhibitors/antagonists
|
US11357748B2
(en)
|
2014-05-30 |
2022-06-14 |
The Johns Hopkins University |
Methods for treating mendelian disorders of the epigenetic machinery
|
SG10201703965SA
(en)
|
2014-06-03 |
2017-06-29 |
Xbiotech Inc |
Compositions and methods for treating and preventing staphylococcus aureus infections
|
BR112016028567A2
(en)
|
2014-06-09 |
2018-01-30 |
Kyowa Hakko Kirin Co Ltd |
method for using anti-fgf23 ligand and for treating fgf23-related disease and / or condition and increasing bone remodeling
|
BR112016029211A2
(en)
|
2014-06-13 |
2018-01-30 |
Amgen Inc |
composition, method for inhibiting solid tumor growth in an individual, method for producing a protein, method for inhibiting, reducing or treating cachexia in an individual, method for treating obesity or an obesity-associated disease and kit
|
TW201625299A
(en)
|
2014-06-20 |
2016-07-16 |
Chugai Pharmaceutical Co Ltd |
Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii
|
CN106715418A
(en)
|
2014-07-07 |
2017-05-24 |
基因泰克公司 |
Therapeutic compounds and methods of use thereof
|
US10166304B2
(en)
|
2014-07-11 |
2019-01-01 |
Regents Of The University Of Minnesota |
Antibody fragments for detecting cancer and methods of use
|
JP6749312B2
(en)
|
2014-07-31 |
2020-09-02 |
アムゲン リサーチ (ミュンヘン) ゲーエムベーハーAMGEN Research(Munich)GmbH |
Optimized interspecific bispecific single chain antibody constructs
|
AR101669A1
(en)
|
2014-07-31 |
2017-01-04 |
Amgen Res (Munich) Gmbh |
ANTIBODY CONSTRUCTS FOR CDH19 AND CD3
|
US20170216403A1
(en)
|
2014-08-12 |
2017-08-03 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
|
DK3180018T3
(en)
|
2014-08-12 |
2019-10-28 |
Massachusetts Inst Technology |
Synergistic tumor treatment with IL-2 and integrin-binding Fc fusion protein
|
EA201790434A1
(en)
|
2014-08-22 |
2017-07-31 |
Окленд Юнисервисиз Лимитед |
CHANNEL MODULATORS
|
EP3186378A1
(en)
|
2014-08-27 |
2017-07-05 |
Peptimed, Inc. |
Anti-tumor compositions and methods
|
WO2016040767A2
(en)
|
2014-09-12 |
2016-03-17 |
Amgen Inc. |
Chrdl-1 epitopes and antibodies
|
EP3000814A1
(en)
|
2014-09-26 |
2016-03-30 |
Domain Therapeutics |
Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
|
CN113855806A
(en)
|
2014-10-21 |
2021-12-31 |
赛生药品股份国际有限公司 |
Treatment of cancer with immunostimulants
|
EA036697B1
(en)
|
2014-10-24 |
2020-12-09 |
Бристол-Майерс Сквибб Компани |
Modified fgf-21 polypeptides and uses thereof
|
WO2016069889A1
(en)
|
2014-10-31 |
2016-05-06 |
Resolve Therapeutics, Llc |
Therapeutic nuclease-transferrin fusions and methods
|
WO2016079321A1
(en)
|
2014-11-20 |
2016-05-26 |
Cemm Forschungszentrum Für Molekulare Medizin Gmbh |
Antagonists of setdb2 for use in the therapy of infectious diseases
|
EP3085709B1
(en)
|
2014-12-28 |
2019-08-21 |
Genor Biopharma Co., Ltd |
Humanized anti-human rankl antibody, pharmaceutical composition and use thereof
|
JP6912386B2
(en)
|
2015-01-26 |
2021-08-04 |
ザ ユニバーシティー オブ シカゴ |
CAR T cells that recognize cancer-specific IL13Rα2
|
JP7264592B2
(en)
|
2015-01-26 |
2023-04-25 |
ザ ユニバーシティー オブ シカゴ |
IL13Rα2 BINDING AGENTS AND THEIR USE IN CANCER THERAPY
|
WO2016135139A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
2,3-dihydrocyclopenta[b]quinoline derivatives as mth1 inhibitors for the therapy of cancer
|
WO2016135140A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer
|
WO2016135137A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Substituted 4-(phenylamino)quinoline derivatives as mth1 inhibitors for the therapy of cancer
|
AU2016223584B2
(en)
|
2015-02-23 |
2020-11-19 |
Enrico GIRAUDO |
Non-natural Semaphorins 3 and their medical use
|
WO2016135138A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer
|
TWI805046B
(en)
|
2015-02-27 |
2023-06-11 |
日商中外製藥股份有限公司 |
Use of IL-6 receptor antibody for preparing pharmaceutical composition
|
WO2016142310A1
(en)
|
2015-03-09 |
2016-09-15 |
F. Hoffmann-La Roche Ag |
Tricyclic dlk inhibitors and uses thereof
|
WO2016154621A1
(en)
|
2015-03-26 |
2016-09-29 |
The California Institute For Biomedical Research |
SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
|
MX2017012966A
(en)
|
2015-04-10 |
2018-06-06 |
Amgen Inc |
Interleukin-2 muteins for the expansion of t-regulatory cells.
|
US11091546B2
(en)
|
2015-04-15 |
2021-08-17 |
The Scripps Research Institute |
Optimized PNE-based chimeric receptor T cell switches and uses thereof
|
EP4276116A3
(en)
|
2015-04-17 |
2024-01-17 |
Amgen Research (Munich) GmbH |
Bispecific antibody constructs for cdh3 and cd3
|
US10864190B2
(en)
|
2015-04-22 |
2020-12-15 |
CeMM—FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GmbH |
Combination of an antiandrogen with a vitamin K antagonist or with a gamma-glutamyl carboxylase inhibitor for the therapy of androgen receptor positive cancer
|
US20180146703A1
(en)
*
|
2015-05-15 |
2018-05-31 |
The Johns Hopkins University |
Novel fluoride prenatal dietary supplement
|
MX2017014715A
(en)
|
2015-05-22 |
2018-03-16 |
Genentech Inc |
Substituted benzamides and methods of use thereof.
|
US20160361380A1
(en)
|
2015-06-12 |
2016-12-15 |
Nymox Corporation |
Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
|
CN107921098A
(en)
|
2015-06-17 |
2018-04-17 |
加州生物医学研究所 |
Therapeutic agent of modification and combinations thereof
|
WO2017007955A1
(en)
|
2015-07-07 |
2017-01-12 |
The Research Foundation For The State University Of New York |
Use of amine carboxyboranes as therapeutic delivery of carbon monoxide and as general drug delivery system in the presence of reactive oxygen species
|
US10842763B2
(en)
|
2015-07-31 |
2020-11-24 |
The Johns Hopkins University |
Methods for cancer and immunotherapy using prodrugs of glutamine analogs
|
WO2017023791A1
(en)
|
2015-07-31 |
2017-02-09 |
The Johns Hopkins University |
Glutamine antagonists for the treatment of cognitive deficits
|
TWI796283B
(en)
|
2015-07-31 |
2023-03-21 |
德商安美基研究(慕尼黑)公司 |
Antibody constructs for msln and cd3
|
TWI829617B
(en)
|
2015-07-31 |
2024-01-21 |
德商安美基研究(慕尼黑)公司 |
Antibody constructs for flt3 and cd3
|
SI3328827T1
(en)
|
2015-07-31 |
2023-11-30 |
The Johns Hopkins University |
Prodrugs of glutamine analogs
|
CN108135875B
(en)
|
2015-07-31 |
2021-12-31 |
约翰霍普金斯大学 |
Methods and compositions for treating metabolic reprogramming disorders
|
TWI717375B
(en)
|
2015-07-31 |
2021-02-01 |
德商安美基研究(慕尼黑)公司 |
Antibody constructs for cd70 and cd3
|
TWI744242B
(en)
|
2015-07-31 |
2021-11-01 |
德商安美基研究(慕尼黑)公司 |
Antibody constructs for egfrviii and cd3
|
TWI793062B
(en)
|
2015-07-31 |
2023-02-21 |
德商安美基研究(慕尼黑)公司 |
Antibody constructs for dll3 and cd3
|
JO3620B1
(en)
|
2015-08-05 |
2020-08-27 |
Amgen Res Munich Gmbh |
Immune-checkpoint inhibitors for use in the treatment of blood-borne cancers cancers
|
JP2018526371A
(en)
|
2015-08-27 |
2018-09-13 |
ジェネンテック, インコーポレイテッド |
Therapeutic compounds and methods of use thereof
|
AU2016315889A1
(en)
|
2015-09-04 |
2018-03-22 |
The California Institute For Biomedical Research |
Insulin immunoglobulin fusion proteins
|
US20180280474A1
(en)
|
2015-10-01 |
2018-10-04 |
Amgen Inc. |
Treatment of bile acid disorders
|
WO2017079215A1
(en)
|
2015-11-03 |
2017-05-11 |
Glycomimetics, Inc. |
Methods and compositions for the production of monoclonal antibodies, hematopoietic stem cells, and methods of using the same
|
CA3004680A1
(en)
|
2015-11-13 |
2017-05-18 |
Mavalon Therapeutics Limited |
Substituted tricyclic 1,4-benzodiazepinone derivatives as allosteric modulators of group ii metabotropic glutamate receptors
|
JP6925278B2
(en)
|
2015-11-18 |
2021-08-25 |
中外製薬株式会社 |
Method of enhancing humoral immune response
|
EP3378487B1
(en)
|
2015-11-18 |
2022-03-16 |
Chugai Seiyaku Kabushiki Kaisha |
Combination therapy using t cell redirection antigen binding molecule against cell having immunosuppressing function
|
MA43304A
(en)
|
2015-11-25 |
2018-10-03 |
Genentech Inc |
SUBSTITUTE BENZAMIDES USEFUL AS SODIUM CHANNEL BLOCKERS
|
WO2017096262A1
(en)
|
2015-12-04 |
2017-06-08 |
Jomoco, Corp. |
Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
|
DK3387019T3
(en)
|
2015-12-09 |
2022-01-10 |
Scripps Research Inst |
RELAXIN-IMMUNOGLOBULIN INFUSION PROTEINS AND METHODS OF USE
|
WO2017097986A1
(en)
|
2015-12-09 |
2017-06-15 |
Medizinische Universität Wien |
Monomaleimide-functionalized platinum compounds for cancer therapy
|
PE20181327A1
(en)
|
2015-12-23 |
2018-08-20 |
Amgen Inc |
METHOD TO TREAT OR IMPROVE METABOLIC DISORDERS WITH GASTRIC INHIBITOR PEPTIDE RECEPTOR BINDING PROTEINS (GIPR) IN COMBINATION WITH GLP-1 AGONISTS
|
JP6954842B2
(en)
|
2015-12-25 |
2021-10-27 |
中外製薬株式会社 |
Antibodies with enhanced activity and methods for modifying them
|
JP2019508383A
(en)
|
2016-01-15 |
2019-03-28 |
ウニベルジテート ハンブルグUniversitaet Hamburg |
Flavonoid-type compound having O-rhamnosyl residue
|
JOP20170017B1
(en)
|
2016-01-25 |
2021-08-17 |
Amgen Res Munich Gmbh |
Pharmaceutical composition comprising bispecific antibody constructs
|
EA039859B1
(en)
|
2016-02-03 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Bispecific antibody constructs binding egfrviii and cd3
|
EP3411404B1
(en)
|
2016-02-03 |
2022-11-09 |
Amgen Research (Munich) GmbH |
Psma and cd3 bispecific t cell engaging antibody constructs
|
KR20180103084A
(en)
|
2016-02-03 |
2018-09-18 |
암젠 리서치 (뮌헨) 게엠베하 |
BCMA and CD3 bispecific T cell engrafting antibody constructs
|
US10098909B2
(en)
|
2016-02-05 |
2018-10-16 |
University Of South Florida |
Ionic cocrystal of lithium, lispro, for the treatment of fragile X syndrome
|
RU2732502C2
(en)
|
2016-02-10 |
2020-09-18 |
Ратгерс, Де Стейт Юниверсити Оф Нью Джерси |
Novel monoclonal antibodies to lam and pim6/lam for diagnosing and treating infections caused by mycobacterium tuberculosis
|
CA3013988A1
(en)
|
2016-02-15 |
2017-08-24 |
Cemm-Forschungszentrum Fur Molekulare Medizin Gmbh |
Taf1 inhibitors for the therapy of cancer
|
EP3216458A1
(en)
|
2016-03-07 |
2017-09-13 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Modified vascular endothelial growth factor a (vegf-a) and its medical use
|
TW202342540A
(en)
|
2016-03-14 |
2023-11-01 |
日商中外製藥股份有限公司 |
Cell injury inducing therapeutic drug for use in cancer therapy
|
EP3854782A1
(en)
|
2016-03-30 |
2021-07-28 |
Genentech, Inc. |
Substituted benzamides and methods of use thereof
|
GB2555264A
(en)
|
2016-04-15 |
2018-04-25 |
Univ Oxford Innovation Ltd |
Adenosine receptor modulators for the treatment of circadian rhythm disorders
|
KR20180133198A
(en)
|
2016-05-04 |
2018-12-13 |
암젠 인크 |
Interleukin-2 mutein for proliferation of T-regulatory cells
|
US10183058B2
(en)
|
2016-06-17 |
2019-01-22 |
Nymox Corporation |
Method of preventing or reducing the progression of prostate cancer
|
MA45554A
(en)
|
2016-07-01 |
2019-05-08 |
Resolve Therapeutics Llc |
OPTIMIZED BINUCLEASE FUSIONS.
|
US10300145B2
(en)
|
2016-07-15 |
2019-05-28 |
Massachusetts Institute Of Technology |
Synthetic nanoparticles for delivery of immunomodulatory compounds
|
WO2018015410A1
(en)
|
2016-07-20 |
2018-01-25 |
F. Hoffmann-La Roche Ag |
Bicyclic proline compounds
|
WO2018015411A1
(en)
|
2016-07-20 |
2018-01-25 |
F. Hoffmann-La Roche Ag |
Sulfonylcycloalkyl carboxamide compounds as trpa1 modulators
|
US10172910B2
(en)
|
2016-07-28 |
2019-01-08 |
Nymox Corporation |
Method of preventing or reducing the incidence of acute urinary retention
|
US20200030295A1
(en)
|
2016-08-02 |
2020-01-30 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Heterocyclic diamidines
|
CN110214021A
(en)
|
2016-08-08 |
2019-09-06 |
安进公司 |
Improve the method for connective tissue attachment using anti-hardened proteins antibody
|
JP7071959B2
(en)
|
2016-08-12 |
2022-05-19 |
エフ.ホフマン-ラ ロシュ アーゲー |
Sulfonylpyridyl TRP inhibitor
|
WO2018044970A1
(en)
|
2016-08-31 |
2018-03-08 |
University Of Rochester |
Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof
|
US10532081B2
(en)
|
2016-09-07 |
2020-01-14 |
Nymox Corporation |
Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
|
CA3032046A1
(en)
|
2016-09-16 |
2018-03-22 |
Research Triangle Institute |
Tetrahydroisoquinoline kappa opioid antagonists
|
JP7349359B2
(en)
|
2016-10-17 |
2023-09-22 |
エフ. ホフマン-ラ ロシュ アーゲー |
Bicyclic pyridone lactams and methods of using them.
|
AU2017345479B2
(en)
|
2016-10-19 |
2024-03-21 |
The Scripps Research Institute |
Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
|
AU2017359288A1
(en)
|
2016-11-14 |
2019-05-30 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Combination of a BRD4 inhibitor and an antifolate for the therapy of cancer
|
WO2018096159A1
(en)
|
2016-11-28 |
2018-05-31 |
F. Hoffmann-La Roche Ag |
Oxadiazolones as transient receptor potential channel inhibitors
|
JP7166252B2
(en)
|
2016-11-30 |
2022-11-07 |
メディツィーニシェ・ウニヴェルジテート・インスブルック |
3-amino-1,5-dihydropyrazolo[3,4-d]pyrimidin-4-ones as cyclin-dependent kinase inhibitors
|
US11071721B2
(en)
|
2016-12-02 |
2021-07-27 |
Genentech, Inc. |
Bicyclic amide compounds and methods of use thereof
|
US11072607B2
(en)
|
2016-12-16 |
2021-07-27 |
Genentech, Inc. |
Inhibitors of RIP1 kinase and methods of use thereof
|
WO2018128454A1
(en)
|
2017-01-06 |
2018-07-12 |
에이비엘바이오 주식회사 |
ANTI-α-SYN ANTIBODY AND USE THEREOF
|
US10603358B2
(en)
|
2017-01-10 |
2020-03-31 |
Nodus Therapeutics |
Combination tumor treatment with an integrin-binding-Fc fusion protein and immune stimulator
|
US10350266B2
(en)
|
2017-01-10 |
2019-07-16 |
Nodus Therapeutics, Inc. |
Method of treating cancer with a multiple integrin binding Fc fusion protein
|
EP3568143B1
(en)
|
2017-01-11 |
2023-12-13 |
Paracelsus Medizinische Privatuniversität Salzburg - Privatstiftung |
Mesenchymal stem cell-derived extracellular vesicles and their medical use
|
JOP20190177A1
(en)
|
2017-01-17 |
2019-07-16 |
Amgen Inc |
Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)
|
JOP20190189A1
(en)
|
2017-02-02 |
2019-08-01 |
Amgen Res Munich Gmbh |
Low ph pharmaceutical composition comprising t cell engaging antibody constructs
|
CA3052639A1
(en)
|
2017-02-08 |
2018-08-16 |
Bristol-Myers Squibb Company |
Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
|
US10335453B2
(en)
|
2017-03-01 |
2019-07-02 |
Nymox Corporation |
Compositions and methods for improving sexual function
|
US11021529B2
(en)
|
2017-03-03 |
2021-06-01 |
Massachusetts Institute Of Technology |
Antimicrobial constructs and uses thereof
|
JP7178357B2
(en)
|
2017-03-07 |
2022-11-25 |
エフ.ホフマン-ラ ロシュ アーゲー |
Oxadiazole transient receptor potential channel inhibitor
|
WO2018175707A1
(en)
|
2017-03-24 |
2018-09-27 |
Genentech, Inc. |
4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors
|
JP7185884B2
(en)
|
2017-05-02 |
2022-12-08 |
国立研究開発法人国立精神・神経医療研究センター |
METHOD FOR PREDICTING AND DETERMINING THERAPEUTIC EFFECT OF IL-6 AND NEUTROPHIL-RELATED DISEASE
|
WO2018204907A1
(en)
|
2017-05-05 |
2018-11-08 |
Amgen Inc. |
Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
|
AU2018265615A1
(en)
|
2017-05-12 |
2019-10-03 |
Domain Therapeutics |
Substituted heterocyclic compounds as allosteric modulators of group II metabotropic glutamate receptors
|
CA3062749A1
(en)
|
2017-05-12 |
2018-11-15 |
Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. |
Compounds for use in the treatment or prevention of melanoma
|
JOP20190259A1
(en)
|
2017-05-31 |
2019-10-31 |
Amgen Inc |
Anti-jagged1 antigen binding proteins
|
WO2018236904A1
(en)
|
2017-06-19 |
2018-12-27 |
Surface Oncology, Inc. |
Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof
|
BR112019024410A2
(en)
|
2017-06-20 |
2020-07-14 |
Amgen Inc. |
method of treating or improving metabolic disorders using gastric inhibitory peptide receptor (gipr) binding proteins in combination with glp 1 agonists
|
MX2020000342A
(en)
|
2017-07-11 |
2020-08-17 |
Compass Therapeutics Llc |
Agonist antibodies that bind human cd137 and uses thereof.
|
CA3185865A1
(en)
|
2017-07-14 |
2019-01-17 |
F. Hoffmann-La Roche Ag |
Bicyclic ketone compounds and methods of use thereof
|
CA3070089A1
(en)
|
2017-07-19 |
2019-01-24 |
Auckland Uniservices Limited |
Cytokine modulation
|
WO2019032827A1
(en)
|
2017-08-09 |
2019-02-14 |
Massachusetts Institute Of Technology |
Albumin binding peptide conjugates and methods thereof
|
SG11202001311VA
(en)
|
2017-08-22 |
2020-03-30 |
Sanabio Llc |
Soluble interferon receptors and uses thereof
|
KR20200055037A
(en)
|
2017-09-19 |
2020-05-20 |
메사추세츠 인스티튜트 오브 테크놀로지 |
Compositions and uses for chimeric antigen receptor T cell therapy
|
SG11202003114UA
(en)
|
2017-10-04 |
2020-05-28 |
Amgen Inc |
Transthyretin immunoglobulin fusions
|
KR20200070297A
(en)
|
2017-10-11 |
2020-06-17 |
에프. 호프만-라 로슈 아게 |
Bicyclic compounds for use as RIP1 kinase inhibitors
|
KR20200074160A
(en)
|
2017-10-20 |
2020-06-24 |
가꼬우호우징 효고 이카다이가쿠 |
Pharmaceutical composition for inhibiting post-surgical adhesion containing anti-IL-6 receptor antibody
|
EP3704132A4
(en)
|
2017-10-30 |
2021-07-28 |
Enterin, Inc. |
New squalamine solid forms and methods of making the same
|
WO2019089753A2
(en)
|
2017-10-31 |
2019-05-09 |
Compass Therapeutics Llc |
Cd137 antibodies and pd-1 antagonists and uses thereof
|
PE20211247A1
(en)
|
2017-10-31 |
2021-07-13 |
Hoffmann La Roche |
SULFONES AND BICYCLE SULFOXIDES AND METHODS OF USING THEM
|
WO2019100052A2
(en)
|
2017-11-20 |
2019-05-23 |
Compass Therapeutics Llc |
Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
WO2019110139A1
(en)
|
2017-12-05 |
2019-06-13 |
Eth Zurich |
New compounds for use as a therapeutically active substance and in particular for use in the treatment of tumors
|
EP3724229A1
(en)
|
2017-12-11 |
2020-10-21 |
Amgen Inc. |
Continuous manufacturing process for bispecific antibody products
|
KR20200101954A
(en)
|
2017-12-19 |
2020-08-28 |
메사추세츠 인스티튜트 오브 테크놀로지 |
Antigen-adjuvant coupling reagents and methods of use
|
WO2019131988A1
(en)
|
2017-12-28 |
2019-07-04 |
Chugai Seiyaku Kabushiki Kaisha |
Cytotoxicity-inducing therapeutic agent
|
TW201940518A
(en)
|
2017-12-29 |
2019-10-16 |
美商安進公司 |
Bispecific antibody construct directed to MUC17 and CD3
|
US20210363238A1
(en)
|
2018-01-31 |
2021-11-25 |
Motokazu Kato |
Therapeutic agent for asthma containing il-6 inhibitor
|
WO2019155427A1
(en)
|
2018-02-09 |
2019-08-15 |
Nestlé Skin Health Sa |
Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation
|
AR114585A1
(en)
|
2018-02-20 |
2020-09-23 |
Hoffmann La Roche |
PROCESS FOR PREPARING ANTAGONIST COMPOUNDS OF POTENTIAL TRANSIENT CHANNELS OF THE 1-ARYLSULFONYL-PYRROLIDIN-2-CARBOXAMIDE RECEPTOR AND CRYSTALLINE FORMS THEREOF
|
US11028075B2
(en)
|
2018-02-26 |
2021-06-08 |
Genentech, Inc. |
Therapeutic compounds and methods of use thereof
|
KR102411489B1
(en)
|
2018-03-14 |
2022-06-23 |
서피스 온콜로지, 인크. |
Antibodies that bind to CD39 and uses thereof
|
US10710994B2
(en)
|
2018-03-19 |
2020-07-14 |
Genentech, Inc. |
Oxadiazole transient receptor potential channel inhibitors
|
US11332524B2
(en)
|
2018-03-22 |
2022-05-17 |
Surface Oncology, Inc. |
Anti-IL-27 antibodies and uses thereof
|
KR20200138254A
(en)
|
2018-03-30 |
2020-12-09 |
암젠 인크 |
C-terminal antibody variant
|
US10947251B2
(en)
|
2018-03-30 |
2021-03-16 |
Genentech, Inc. |
Therapeutic compounds and methods of use thereof
|
CA3096146A1
(en)
|
2018-04-06 |
2019-10-10 |
Zilentin AG |
Bumetanide derivatives for the therapy of hyperhidrosis
|
US20210163406A1
(en)
|
2018-04-06 |
2021-06-03 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Bumetanide Derivatives for the Therapy of Stroke and Other Neurological Diseases/Disorders Involving NKCCs
|
CR20200510A
(en)
|
2018-04-09 |
2020-11-26 |
Amgen Inc |
Growth differentiation factor 15 fusion proteins
|
WO2019200357A1
(en)
|
2018-04-12 |
2019-10-17 |
Surface Oncology, Inc. |
Biomarker for cd47 targeting therapeutics and uses therefor
|
US10907161B2
(en)
|
2018-04-19 |
2021-02-02 |
Checkmate Pharmaceuticals, Inc. |
Synthetic RIG-I-like receptor agonists
|
CN112074519A
(en)
|
2018-04-20 |
2020-12-11 |
豪夫迈·罗氏有限公司 |
N- [ 4-oxo-2, 3-dihydro-1, 5-benzoxazepin-3-yl ] -5, 6-dihydro-4H-pyrrolo [1,2-B ] pyrazole-2-carboxamide derivatives and related compounds as RIP1 kinase inhibitors for the treatment of e.g. Irritable Bowel Syndrome (IBS)
|
WO2019207051A1
(en)
|
2018-04-25 |
2019-10-31 |
Università Degli Studi Di Torino |
Medical use of combinations of non-natural semaphorins 3 and antimetabolites
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
WO2019226617A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Compositions and methods for enhancing the killing of target cells by nk cells
|
TW202003490A
(en)
|
2018-05-22 |
2020-01-16 |
瑞士商赫孚孟拉羅股份公司 |
Therapeutic compounds and methods of use thereof
|
WO2019225787A1
(en)
|
2018-05-24 |
2019-11-28 |
에이비엘바이오 주식회사 |
Anti-b7-h3 antibody and use thereof
|
WO2020011938A1
(en)
|
2018-07-11 |
2020-01-16 |
Medizinische Universität Wien |
Glucocorticoids for the topical treatment of autoimmune gastritis
|
US20220275043A1
(en)
|
2018-07-17 |
2022-09-01 |
Massachusetts Institute Of Technology |
Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
|
US20210388089A1
(en)
|
2018-08-09 |
2021-12-16 |
Compass Therapeutics Llc |
Antigen binding agents that bind cd277 and uses thereof
|
WO2020033925A2
(en)
|
2018-08-09 |
2020-02-13 |
Compass Therapeutics Llc |
Antibodies that bind cd277 and uses thereof
|
WO2020033926A2
(en)
|
2018-08-09 |
2020-02-13 |
Compass Therapeutics Llc |
Antibodies that bind cd277 and uses thereof
|
CN111417655A
(en)
|
2018-08-28 |
2020-07-14 |
润俊(中国)有限公司 |
anti-CD3 antibody folate bioconjugates and uses thereof
|
JP2021535169A
(en)
|
2018-09-03 |
2021-12-16 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
Carboxamide and sulfonamide derivatives useful as TEAD modulators
|
FI3849614T3
(en)
|
2018-09-11 |
2024-02-08 |
Ambrx Inc |
Interleukin-2 polypeptide conjugates and their uses
|
WO2020053808A1
(en)
|
2018-09-12 |
2020-03-19 |
Georg Dewald |
Method of diagnosing vasoregulatory disorders
|
JP2022502037A
(en)
|
2018-09-28 |
2022-01-11 |
マサチューセッツ インスティテュート オブ テクノロジー |
Immunomodulatory molecules localized to collagen and their methods
|
JP2022512636A
(en)
|
2018-10-11 |
2022-02-07 |
アムジエン・インコーポレーテツド |
Downstream processing of bispecific antibody constructs
|
JP2022512746A
(en)
|
2018-10-19 |
2022-02-07 |
アンブルックス,インコーポレイテッド |
Interleukin-10 polypeptide complex, its dimer, and their use
|
CA3122354A1
(en)
|
2018-12-17 |
2020-06-25 |
Tolremo Therapeutics Ag |
Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of cancer
|
MX2021008081A
(en)
|
2019-01-04 |
2021-08-05 |
Resolve Therapeutics Llc |
Treatment of sjogren's disease with nuclease fusion proteins.
|
EP3908586B1
(en)
|
2019-01-11 |
2022-12-21 |
F. Hoffmann-La Roche AG |
Bicyclic pyrrolotriazolr ketone compounds and methods of use thereof
|
US11680105B2
(en)
|
2019-01-17 |
2023-06-20 |
Regents Of The University Of Minnesota |
Antibody fragments for detecting cancer and methods of use
|
WO2020154032A1
(en)
|
2019-01-23 |
2020-07-30 |
Massachusetts Institute Of Technology |
Combination immunotherapy dosing regimen for immune checkpoint blockade
|
US11236157B2
(en)
|
2019-01-28 |
2022-02-01 |
Galderma Holding SA |
Treatment of skin lesions and pruritus in prurigo nodularis patients
|
BR112021015832A2
(en)
|
2019-02-12 |
2022-01-18 |
Ambrx Inc |
Compositions containing antibody-tlr agonist conjugates, methods and uses thereof
|
EP3941511A2
(en)
|
2019-03-20 |
2022-01-26 |
Massachusetts Institute of Technology |
Uses of amphiphiles in immune cell therapy and compositions therefor
|
EP3949989A4
(en)
|
2019-03-29 |
2022-12-14 |
Chugai Seiyaku Kabushiki Kaisha |
Anti il-6 receptor antibody-containing inhibitor for inhibiting deterioration of bbb function
|
US20220204608A1
(en)
|
2019-04-17 |
2022-06-30 |
Hiroshima University |
Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination
|
US20220193113A1
(en)
|
2019-05-31 |
2022-06-23 |
Osaka University |
Novel therapeutic agent for gastrointestinal cancer and method for screening for the same
|
EP4023230A4
(en)
|
2019-06-05 |
2023-11-15 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody cleavage site-binding molecule
|
CR20220008A
(en)
|
2019-06-10 |
2022-02-11 |
Chugai Pharmaceutical Co Ltd |
Anti-t cell antigen-binding molecule to be used in combination with cytokine inhibitor
|
TW202045711A
(en)
|
2019-06-13 |
2020-12-16 |
美商安進公司 |
Automated biomass-based perfusion control in the manufacturing of biologics
|
EP3990491A1
(en)
|
2019-06-26 |
2022-05-04 |
Massachusetts Institute of Technology |
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
|
CN114127125A
(en)
|
2019-07-08 |
2022-03-01 |
安进公司 |
Multispecific thyroxin transporter immunoglobulin fusions
|
CN113950485A
(en)
|
2019-07-10 |
2022-01-18 |
中外制药株式会社 |
Claudin-6 binding molecules and uses thereof
|
MX2022000988A
(en)
|
2019-07-26 |
2022-05-03 |
Amgen Inc |
Anti-il13 antigen binding proteins.
|
EP4013788A1
(en)
|
2019-08-12 |
2022-06-22 |
Purinomia Biotech, Inc. |
Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells
|
MX2022001866A
(en)
|
2019-08-13 |
2022-03-11 |
Amgen Inc |
Interleukin-2 muteins for the expansion of t-regulatory cells.
|
WO2021055329A1
(en)
|
2019-09-16 |
2021-03-25 |
Surface Oncology, Inc. |
Anti-cd39 antibody compositions and methods
|
AU2020353672A1
(en)
|
2019-09-25 |
2022-03-31 |
Surface Oncology, LLC |
Anti-IL-27 antibodies and uses thereof
|
WO2021064141A1
(en)
|
2019-10-02 |
2021-04-08 |
Tolremo Therapeutics Ag |
Inhibitors of dual specificity tyrosine phosphorylation regulated kinase 1b
|
JP7395723B2
(en)
|
2019-10-02 |
2023-12-11 |
トルレモ・セラピューティクス・アクチェンゲゼルシャフト |
Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer
|
WO2021070885A1
(en)
|
2019-10-11 |
2021-04-15 |
中外製薬株式会社 |
Pharmaceutical composition which can be used for prevention and/or treatment of acquired hemophilia a, and product comprising said pharmaceutical composition
|
IL292153A
(en)
|
2019-10-16 |
2022-06-01 |
Cemm Forschungszentrum Fur Molekulare Medizin Gmbh |
Oxazole and thioazole-type cullin ring ubiquitin ligase compounds and uses thereof
|
WO2021074418A1
(en)
|
2019-10-16 |
2021-04-22 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Carbazole-type cullin ring ubiquitin ligase compounds and uses thereof
|
US20220378817A1
(en)
|
2019-10-23 |
2022-12-01 |
Checkmate Pharmaceuticals, Inc. |
Synthetic rig-i-like receptor agonists
|
US11459389B2
(en)
|
2019-10-24 |
2022-10-04 |
Massachusetts Institute Of Technology |
Monoclonal antibodies that bind human CD161
|
AU2020371784A1
(en)
|
2019-10-24 |
2022-06-02 |
Minotaur Therapeutics, Inc. |
Chimeric cytokine modified antibodies and methods of use thereof
|
CA3155989A1
(en)
|
2019-11-13 |
2021-05-20 |
Jason Robert ZBIEG |
Therapeutic compounds and methods of use
|
CA3156683A1
(en)
|
2019-11-13 |
2021-05-20 |
Amgen Inc. |
Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
|
AU2020386151B2
(en)
|
2019-11-19 |
2023-09-21 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Novel compounds for the diagnosis, treatment and prevention of diseases associated with the aggregation of alpha-synuclein
|
JP2023507115A
(en)
|
2019-12-17 |
2023-02-21 |
アムジエン・インコーポレーテツド |
Dual interleukin-2/TNF receptor agonist for use in therapy
|
CA3160204A1
(en)
|
2020-01-06 |
2021-07-15 |
Vaccinex, Inc. |
Anti-ccr8 antibodies and uses thereof
|
WO2021173889A1
(en)
|
2020-02-26 |
2021-09-02 |
Ambrx, Inc. |
Uses of anti-cd3 antibody folate bioconjugates
|
AU2021233909A1
(en)
|
2020-03-11 |
2022-09-29 |
Ambrx, Inc. |
Interleukin-2 polypeptide conjugates and methods of use thereof
|
KR20220155338A
(en)
|
2020-03-19 |
2022-11-22 |
암젠 인크 |
Antibodies to mucin 17 and uses thereof
|
JP2023106635A
(en)
|
2020-04-17 |
2023-08-02 |
中外製薬株式会社 |
Bispecific antigen binding molecules and compositions related thereto, uses, kits and methods for producing compositions
|
WO2021221783A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
WO2021221782A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Chimeric antigen receptor-targeting ligands and uses thereof
|
US20230235036A1
(en)
|
2020-06-05 |
2023-07-27 |
The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glads |
Acvr1 (alk2) receptor inhibition to treat neurological diseases
|
GB202101299D0
(en)
|
2020-06-09 |
2021-03-17 |
Avacta Life Sciences Ltd |
Diagnostic polypetides and methods
|
CR20230014A
(en)
|
2020-06-19 |
2023-02-17 |
Chugai Pharmaceutical Co Ltd |
Anti-t cell antigen-binding molecule for use in combination with angiogenesis inhibitor
|
BR112022026045A2
(en)
|
2020-06-25 |
2023-01-17 |
Tolremo Therapeutics Ag |
HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT, IMPROVEMENT OR PREVENTION OF FIBROTIC DISEASE
|
EP4171614A1
(en)
|
2020-06-29 |
2023-05-03 |
Resolve Therapeutics, LLC |
Treatment of sjogren's syndrome with nuclease fusion proteins
|
EP3939578A1
(en)
|
2020-07-13 |
2022-01-19 |
Novaremed Ltd. |
Compounds for treatment or prevention of an infection resulting from a coronavirus and/or a coronavirus-induced disease
|
US11787775B2
(en)
|
2020-07-24 |
2023-10-17 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
IL300225A
(en)
|
2020-07-31 |
2023-03-01 |
Chugai Pharmaceutical Co Ltd |
Pharmaceutical composition including cell expressing chimeric receptor
|
WO2022023292A2
(en)
|
2020-07-31 |
2022-02-03 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Corona virus spike protein-targeting antibodies and use thereof
|
AU2021327396A1
(en)
|
2020-08-20 |
2023-03-23 |
Ambrx, Inc. |
Antibody-TLR agonist conjugates, methods and uses thereof
|
EP3964497A1
(en)
|
2020-09-04 |
2022-03-09 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Substituted vicinal diamine compounds and their use in the treatment, amelioration or prevention of pain
|
BR112023005853A2
(en)
|
2020-10-02 |
2023-05-02 |
Genentech Inc |
PROCESS FOR PREPARING A COMPOUND OF FORMULA I, COMPOUNDS, PROCESSES FOR PREPARING COMPOUND 1, CRYSTALLINE FORM, PHARMACEUTICAL COMPOSITION, PROCESS FOR PREPARING THE CRYSTALLINE FORM OF COMPOUND I AND METHOD FOR TREATMENT OF A NEURODEGENERATIVE CONDITION
|
WO2022087274A1
(en)
|
2020-10-21 |
2022-04-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies that neutralize type-i interferon (ifn) activity
|
AU2021374839A1
(en)
|
2020-11-06 |
2023-06-08 |
Amgen Inc. |
Multitargeting bispecific antigen-binding molecules of increased selectivity
|
CN117321076A
(en)
|
2021-02-19 |
2023-12-29 |
美国卫生及公众服务部代表 |
Single domain antibodies neutralizing SARS-CoV-2
|
TW202302143A
(en)
|
2021-03-12 |
2023-01-16 |
日商中外製藥股份有限公司 |
Pharmaceutical composition for treatment or prevention of myasthenia gravis
|
WO2022212899A1
(en)
|
2021-04-03 |
2022-10-06 |
Ambrx, Inc. |
Anti-her2 antibody-drug conjugates and uses thereof
|
CN117355512A
(en)
|
2021-04-07 |
2024-01-05 |
托雷莫治疗股份公司 |
Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer
|
WO2022232321A1
(en)
|
2021-04-28 |
2022-11-03 |
Minotaur Therapeutics, Inc. |
Humanized chimeric bovine antibodies and methods of use
|
EP4334358A1
(en)
|
2021-05-06 |
2024-03-13 |
Amgen Research (Munich) GmbH |
Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
|
JP2024516970A
(en)
|
2021-05-07 |
2024-04-18 |
サーフィス オンコロジー, エルエルシー |
Anti-IL-27 antibodies and uses thereof
|
AU2022272740A1
(en)
|
2021-05-14 |
2023-11-02 |
Claris Biotherapeutics, Inc. |
Compositions of growth factor for the treatment of eye disease
|
WO2023028077A1
(en)
|
2021-08-24 |
2023-03-02 |
Genentech, Inc. |
Sodium channel inhibitors and methods of designing same
|
WO2023028056A1
(en)
|
2021-08-24 |
2023-03-02 |
Genentech, Inc. |
3-amino piperidyl sodium channel inhibitors
|
US20230242652A1
(en)
|
2021-08-30 |
2023-08-03 |
Galderma Holding S.A. |
Treatments for atopic dermatitis
|
AR126971A1
(en)
|
2021-09-03 |
2023-12-06 |
Univ Of Bern |
COMPOSITIONS AND METHODS FOR TREATING LONG QT SYNDROME
|
CA3233696A1
(en)
|
2021-11-03 |
2023-05-11 |
Joachim Koch |
Bispecific cd16a binders
|
WO2023079493A1
(en)
|
2021-11-03 |
2023-05-11 |
Affimed Gmbh |
Bispecific cd16a binders
|
WO2023097195A1
(en)
|
2021-11-24 |
2023-06-01 |
Genentech, Inc. |
Therapeutic indazole compounds and methods of use in the treatment of cancer
|
US20230364031A1
(en)
|
2022-04-19 |
2023-11-16 |
Garth Cooper |
Treatment of brain copper disorders
|
WO2023203172A1
(en)
|
2022-04-20 |
2023-10-26 |
Proxygen Gmbh |
Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
|
WO2023218027A1
(en)
|
2022-05-12 |
2023-11-16 |
Amgen Research (Munich) Gmbh |
Multichain multitargeting bispecific antigen-binding molecules of increased selectivity
|
US20240026001A1
(en)
|
2022-05-25 |
2024-01-25 |
Surface Oncology, Inc. |
Use of anti-il-27 antibodies
|
US20240025987A1
(en)
|
2022-05-25 |
2024-01-25 |
Surface Oncology, Inc. |
Use of anti-il-27 antibodies
|
WO2024050526A1
(en)
|
2022-09-02 |
2024-03-07 |
Biomarin Pharmaceutical Inc. |
Compositions and methods for treating long qt syndrome
|
WO2024047497A1
(en)
|
2022-09-02 |
2024-03-07 |
Galderma Holding SA |
Treatments for prurigo nodularis
|
WO2024059675A2
(en)
|
2022-09-14 |
2024-03-21 |
Amgen Inc. |
Bispecific molecule stabilizing composition
|
WO2024076995A1
(en)
|
2022-10-03 |
2024-04-11 |
Insigna Inc. |
Compositions for non-surgical prevention of boar taint and aggressive behavior
|